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ABSTRACT OF DISSERTATION 
 
 
EXPRESSION AND SPLICING OF ALZHEIMER’S DISEASE RISK GENE 
PHOSPHATIDYLINOSITOL-BINDING CLATHRIN ASSEMBLY PROTEIN 
 
Recent Genome Wide Association Studies (GWAS) have identified a 
series of single nucleotide polymorphism (SNP)s that are associated with 
Alzheimer’s disease (AD). One of the SNPs, rs3851179 (G/A), is near the gene 
phosphatidylinositol-binding clathrin assembly protein (PICALM).  To evaluate 
whether this SNP is associated with PICALM expression, we quantified PICALM 
mRNA in 56 brain cDNA samples.  Using linear regression analysis, we analyzed 
PICALM expression relative to rs3851179, AD status, and cell type specific 
markers. An association was detected between rs3851179 and PICALM, 
microvessel mRNA, glial fibrillary acidic protein (GFAP) mRNA, and 
synaptophysin (SYN) mRNA. To gain clarity into other possible SNP 
mechanisms, we searched brain cDNA for PICALM splice variants.  We identified 
several PICALM splice variants involving exons 13-19. To identify and gain an 
estimation of relative abundance of splice variants, we PCR-amplified across 
exons 13-20 in cDNA from six individuals, three rs3851179 GG individuals and 
three rs3851179 AA individuals.  Sequencing the cloned isoforms we found that 
PICALM lacking exon 13 (delta 13) is the most abundant isoform. Other isoforms 
detected included deletion of exon 18-19. We targeted the latter part of the gene, 
exon 17-20, to investigate unequal allelic expression using next generation 
sequencing. Individuals heterozygous for rs76719109 (n= 35), located in exon 
17, were used to study the abundance of G/T allele in cDNA and genomic DNA. 
When we analyzed the T:G allelic ratio, the variant lacking exons 18 and 19 
showed unequal allelic expression (p-value < 0.001) in a subset of individuals.  
One individual was an outlier, showing overall unequal allelic expression, which 
maybe be harboring a rare mutation capable of modifying PICALM expression. 
The PICALM intronic SNP rs588076 was associated with delta 18-19 isoform 
splicing (p-value < 0.001). In conclusion, this study gained a greater insight into 
the role of AD genetics in PICALM expression and splicing.  
KEYWORDS:  PICALM, Alzheimer’s disease, Next-generation sequencing, allelic 
expression imbalance, single nucleotide polymorphism 
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Chapter 1 
Introduction 
 
Alzheimer’s Disease 
 
Impact 
 
Alzheimer’s Disease (AD) is a complex disease with a genetic component 
that affects the aging population. An estimated 5.2 million people in the United 
States and 35.6 million worldwide are affected by the disease. Although 
dementia is seen in various neurodegenerative diseases, with an estimate that 
one in eight older Americans is diagnosed with dementia, AD is the most 
common cause of dementia. Prevalence of the disease will increase as the 
world’s population ages and lives longer due to better healthcare and medical 
advances. Recent projections indicate that by 2030, when the baby boomers will 
be at least 65 years old, there will be more than a 50% increase from the current 
5.2 million people affected. The burden of AD treatment cost can be felt both by 
healthcare programs, as well as the family and friends of the patient that provide 
care while forsaking their income and financial security for a challenging and 
stressful environment. The combined direct and indirect cost of AD is estimated 
to be $214 billion and the projected cost for 2050 balloons to 1.2 trillion dollars 
(Fargo & Bleiler, 2014). 
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History 
 
In 1901, the first case of AD was identified in patient Auguste Deter by 
German psychiatrist Alois Alzheimer. Alzheimer followed the case until her death 
in 1906. Through Alzheimer’s extensive notes we know that Auguste exhibited 
memory deficits, cognitive decline, and paranoia. The autopsy of Auguste’s brain 
showed atrophy and arteriosclerosis of blood vessels (Maurer, Volk, & Gerbaldo, 
1997). Alzheimer’s observed, described and illustrated numerous neurofibrillary 
tangles and amyloid plaques. Thus patients with dementia and this 
neurohistological pathology have subsequently been diagnosed with a disease 
that bears his name, Alzheimer’s Disease.  Although AD is the most common 
cause of dementia, there are other types of dementia that can be present, such 
as vascular dementia or frontotemporal lobar degeneration. Thus an autopsy is 
the only definitive way to diagnose AD.  
 
Diagnosis  
 
Clinically, AD and other causes of dementia are diagnosed by neurological 
exam and mental status tests. One of the commonly used mental exams is the 
Mini-mental state exam (MMSE), where a patient answers a series of questions 
designed to test cognition. It tests the patient’s ability to follow verbal and written 
commands, as well as memory, attention, and orientation. The total maximum 
score for the test is 30 (Folstein, Folstein, & McHugh, 1975). An MMSE score of 
less than 12 suggests severe dementia, whereas 13-20 is considered moderate 
and 20-24 is mild cognitive decline (Fargo & Bleiler, 2014).  
 
Histopathologically, the brain is evaluated for neurofibrillary tangles and 
senile plaques to be diagnosed for AD. Braak Stage classifies extent of 
neurofibrillary tangle accumulation and distribution.  There are a total of six Braak 
stages, and severity of diagnosis increases with each stage (Braak & Braak, 
1991). The Consortium to Establish a Registry for Alzheimer’s disease (CERAD) 
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score evaluates and ranks the density of neuritic plaques in the brain (Mirra et 
al., 1991). Lastly, NIA-Reagan Institute Criteria (NIARI) combines both the 
CERAD and Braak stage scores and evaluates patient’s likelihood of AD 
neuropathologically (Hyman & Trojanowski, 1997). 
 
Although amyloid plaques and neurofibrillary tangles are two hallmarks of 
AD, there are other lesser known lesions and proteins that are also seen in AD; 
such as Hirano bodies, TDP-43, Lewy bodies and granulovacuolar degeneration 
(Perl, 2010; Wilson, Dugger, Dickson, & Wang, 2011). Diagnosis of AD is varied 
and through clinical and histopathological criteria, clinicians and researchers aim 
to have a more concise conclusion of diagnosis. Apart from the neurological 
exams, clinicians have limited tools to diagnose AD. Currently, there are no 
biomarkers or imaging tools to diagnose AD.  Cerebrospinal fluid (CSF) Aβ40 and 
Aβ42 levels are being examined by researchers and clinicians as a tool to 
diagnose AD and assess the progression of mild cognitive impairment to AD.  
Having a more sensitive assessment of AD outcome could lead to early detection 
and a better therapeutic profile (Shaw et al., 2009). Decreased levels of Aβ42 in 
CSF have been seen as a biomarker of AD-related pathologic changes in the 
brain; suggesting more accumulation of Aβ in the brain and less clearance 
(Blennow & Hampel, 2003). Neuroimaging is also another venue for AD 
diagnosis. Pittsburgh compound B (PiB) is a radioactive compound that binds to 
amyloid plaque. PiB has shown promising results in imaging amyloid deposits in 
brain scans in patients (Klunk et al., 2004). The amount of amyloid plaque load in 
a brain scan, in combination with Aβ1-42 in CSF could pave way to helping 
diagnose patients at an earlier stage of AD.  
 
Etiology 
Neuritic or senile plaques consist of amyloid beta peptide (Aβ) aggregate 
deposits in the extracellular matrix of brain. Aβ peptide is a fragment of the 
Amyloid Precursor Protein (APP) (Glenner & Wong, 1984; Kang et al., 1987). 
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Located on the long arm of chromosome 21, APP is a highly conserved gene 
presenting multiple isoforms.  Although APP is ubiquitously expressed, it is highly 
expressed in brain and kidney. In brain, APP function is still unclear.  It has been 
implicated in neuronal development, survival and synaptic density (Oh et al., 
2009; Roch et al., 1994; Young-Pearse et al., 2007).  
 
APP processing is critical in developing AD (Figure 1.1).  APP can be 
proteolyzed by α, β, and γ-secretase to produce multiple products, including Aβ. 
When APP is cleaved by β-secretase and subsequently γ-secretase, proteolysis 
generates Aβ peptide that is 39-42 amino acids. Aβ42 is the more toxic species of 
these peptides; they aggregate and form plaques in the extracellular space. 
Although Aβ42 only accounts for 10% of the Aβ peptide product, it is associated 
with AD plaque pathology; because of its hydrophobic nature it is more inclined 
to fibril formation, and resist proteolytic degradation and clearance (Burdick et al., 
1992; Selkoe, 1998). High Aβ load has been shown to disrupt synaptic function 
and cause neuronal death (Deshpande, Mina, Glabe, & Busciglio, 2006; Shankar 
& Walsh, 2009). A tremendous amount of research has been done on the 
amyloid cascade pathway, however the role environmental and genetic factors 
play in APP processing and Aβ aggregation in propagating sporadic AD is still 
unclear. 
 
Neurofibrillary tangles, another hallmark of AD, consists of 
hyperphosphorylated tau protein within the neuronal cytoplasm. Tau is a 
microtubule binding protein found mostly in neuronal cells axons and functions to 
stabilize microtubules. Alternate splicing of microtubule-associated protein tau 
(MAPT) gene, located on chromosome 17, produces multiple isoforms with 
variable microtubule-binding and phosphorylation sites (Hanger et al., 2007). 
When attached to the microtubules, tau allows the microtubules to be structured 
tracks for axonal transport of vesicles. Typically, tau detaches from the 
microtubules temporarily when phosphorylated, allowing for flexibility. When tau 
protein is hyperphosphorylated, it destabilizes and detaches from the 
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microtubules, causing tau aggregates to form within the neuron (Grundke-Iqbal et 
al., 1986; Schneider, Biernat, von Bergen, Mandelkow, & Mandelkow, 1999).  
Tau tangles have also, like Aβ, been associated with neuronal death and 
synaptic dysfunction (Gamblin et al., 2003; Tai et al., 2012). AD brains have 
more abundant and different phosphorylation sites; current therapeutic targets 
focus on modulating tau phosphorylation through specific kinase inhibitors 
(Hanger et al., 2007; Mudher et al., 2004; Noble, Hanger, Miller, & Lovestone, 
2013).  
 
Susceptibility 
There are two forms of AD: early onset AD and late onset AD. Early onset 
AD or familial AD (FAD) is a rare form of AD and is characterized by being 
affected by dementia at a young age (younger than 65 years old). FAD can have 
Mendelian autosomal dominant form of heredity and can be passed on through 
generations. Through genetic linkage analysis studies gene mutations 
responsible for FAD were discovered. A missense mutation near the β-secretase 
cleavage in APP was the first mutation associated with FAD (Goate et al., 1991). 
Mutations in primarily three genes have been linked to FAD: APP, Presenilin-1 
(PSEN1), and Presenilin-2 (PSEN2) (Schellenberg et al., 1992; Sherrington et 
al., 1995).  Since the early 90s, many mutations have been linked with FAD, 
involving APP processing and Aβ production, particularly near enzymatic 
cleavage sites.  Currently, there are 238 mutations residing in these three genes 
that have been studied for AD. PSEN1 exhibits 185 mutations with pathogenic 
effect and is represented highest in familial genetic screening (Cruts, Theuns, & 
Van Broeckhoven, 2012). There are other genes with mutations that have been 
linked to FAD to a lesser extent, such as FUS, GRN, MAPT, TARDBP, VCP and 
C9orf72. PSEN1 and PSEN2, located on chromosome 14 and 1, respectively, 
are part of γ-secreatase complex that cleaves APP to subsequently produce Aβ.  
Mutations within these genes have been shown to increase Aβ40/Aβ42 ratio 
(Steiner, 2004). Mutations in MAPT have also been linked to FAD, thus piquing 
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researchers’ interest in studying genotype influencing the development of 
pathogenic phenotype, specially in Late On-set AD (LOAD) (Cruts et al., 2012). 
 
LOAD is the sporadic form of AD with age of onset being 65 or older. 
LOAD accounts for up to 95% of AD cases (Eisenstein, 2011). Twin studies 
suggest that approximately 79% of AD is genetic (Avramopoulos, 2009; Gatz et 
al., 2006). A primary genetic risk factor for AD is apolipoprotein E (APOE).  Three 
most common variants of APOE include E2, E3, and E4; one copy of E4 
increases AD risk by 4 fold and two copies by 12-fold (Eisenstein, 2011; O'Brien 
& Wong, 2011).  APOE gene is found on chromosome 19 and encodes for a 
protein that facilitates the transport of lipoproteins throughout the body.  
 
 APOE is primarily produced by microglia and astrocytes in the brain. 
There are several proposed mechanisms through which APOE can modulate AD 
pathology. The primary result shows Aβ clearance is influenced in APOE allele 
dependent manner, where Aβ clearance is disrupted by E4 the most. Aβ binds 
lipidated APOE and is cleared through the blood brain barrier (Liu, Kanekiyo, Xu, 
& Bu, 2013)  
Beyond APOE, researchers have struggled to find single nucleotide 
polymorphism (SNP)s that influence AD onset. It has been difficult to identify 
genes or genetic factors that modulate the disease. Although these variants 
alone are variable in the whole disease population, however the combination of 
different sporadic SNPs may be carried by AD population that affect a gene or 
genes in the same pathway and consequently influence disease onset and 
progression. Due to the heterogeneity of AD, it has been difficult to find risk 
genes with small cohorts and with enough statistical significance. 
 
Genetics of AD 
 Genome-wide association studies (GWAS) have revolutionized the search 
for low penetrative alleles that influence risk for complex diseases and traits. 
Associations made between the genetic variations and phenotype are within a 
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large sample size and span the whole genome, enabling researchers to discover 
risky or protective loci. Over the last couple of years, GWAS have identified many 
risk loci and candidate genes for AD by genotyping SNPs in AD and non-AD 
groups. (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007).  APOE remains the 
highest risk factor for AD within GWA studies, but loci around BIN1, CLU, 
ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, and CD2AP have been 
implicated in AD and are currently the top ten risk genes on Alzgene (Bertram et 
al., 2007). As more studies are conducted in different cohorts and populations, 
additional loci have been implicated in AD, including EPHA1, INPP5D, MEF2C, 
HLA-DRB1-HLA-DRB5, NME8, SLC24A4/RIN3, ZCWPW1, PTK2B, SORL1, 
CELF1, FERMT2, DSG2 and CASS4 (Lambert et al., 2013).  
 
 Understanding how these SNPs are associated with AD is complex for 
several reasons.  First, the association of these SNPs with AD risk does not 
indicate causality of AD phenotype or pathology. Rather, these SNPs contribute 
to risk and have low penetrance.  Second, discerning the gene associated with 
the AD-associated SNP is challenging if multiple genes are present within the 
same genetic linkage disequilibrium (LD) block as the implicated SNP. Third,  a 
large number of these SNPs are not genotyped but imputed based on their LD 
with a genotyped SNP. Thus there is ambiguity about the functional SNPs and 
genes associated with AD.  As more GWA studies and meta-analysis studies are 
conducted there is more confidence within loci. Lastly, the effect of these SNPs 
on AD risk is small such that the accumulated risk of these SNPs may be more 
relevant.  Considering that many of the SNPs implicate genes within similar 
pathways, such as cholesterol homeostasis, inflammation and endocytosis, some 
interaction among the SNPs within a pathway may become clear with further 
studies.  Of particular relevance here, several SNPs in genes associated with 
endocytosis have been associated with AD, including SNPs within BIN1, CD2AP, 
and PICALM.  
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 PICALM is associated with LOAD through multiple GWAS studies. 
PICALM is located on chromosome 11 with the primary SNP, rs3851179, 
~80,000bp 5’ upstream of PICALM.  The minor allele of this SNP reduces AD risk 
with an odds ratio ~0.88. Several other PICALM SNPs have also been 
associated with AD risk: rs561655, rs592297 and rs541458 (Corneveaux et al., 
2010; Harold et al., 2009; Hollingworth et al., 2011; Jun et al., 2010; Lambert et 
al., 2013; Naj et al., 2011; Schjeide et al., 2011). The initial studies were primarily 
performed with Caucasian populations, however when studies were replicated 
and/or performed with different populations, there was no association found 
between AD risk and SNP in Italian, Hispanic, and Chinese populations (Lee et 
al., 2011; Piaceri et al., 2011; Yu et al., 2011). This difference can be interpreted 
as either (i) the SNP effect may be population specific or (ii) these conflicting 
results maybe due to small sample size of the studies, as positive associations 
were seen in other studies and meta-analysis (Feinkohl et al., 2013; T. Jiang et 
al., 2014; G. Liu et al., 2013; Miyashita et al., 2013) 
  
 
Clathrin Mediated Endocytosis and PICALM 
 
 PICALM functions to assist in clathrin coated pit formation. Normal 
regulation of Clathrin Mediated Endocytosis (CME) is critical for cellular 
homeostasis. CME is essential for cellular functions such as cell-to-cell 
communication, cell surface protein regulation and protein recycling. Different 
proteins facilitate clathrin coat formation through distinct stages of coat 
development (Ramanan et al., 2011b). These proteins, including PICALM, are 
collectively called clathrin assembly proteins. PICALM binds phosphatidylinositol 
4,5-bisphosphate (PIP2), adaptor protein 2 (AP2), and clathrin. PIP2 is abundantly 
present in plasma membrane. Clathrin and AP2 are involved in the early phase of 
vesicle formation, which consists of nucleation and invagination. PICALM 
contains a N-terminal globular PIP2 binding module called ANTH (AP180 N-
terminal Homology) domain (Dreyling et al., 1996). PICALM motifs that bind AP2 
 9 
include 375DIF, 420DPF and 489FESVF, which are encoded by exons 11, 13, and 
14, respectively. PICALM motifs that bind clathrin are primarily in the PICALM C-
terminal region and secondarily a weak binding site at the 392DLLDLQ motif 
encoded by exon 12 (Dreyling et al., 1996; Meyerholz et al., 2005) (Figure 1.2). 
Organization of the clathrin coat is influenced by PICALM as the size and shape 
of clathrin-coated vesicles is altered with overexpression or knockdown of 
PICALM (Meyerholz et al., 2005; Tebar, Bohlander, & Sorkin, 1999). 
 
PICALM and AD 
 APP trafficking and cleavage appears central to development of AD. CME 
plays a role in APP internalized from the cell membrane and subsequent amyloid 
beta generation, suggesting a possible relationship PICALM could have with AD. 
CME proteins, including PICALM, are significantly increased in transgenic mice 
AD (Koo & Squazzo, 1994; Thomas, Lelos, Good, & Kidd, 2011). In neurons, 
PICALM has been shown to influence cell surface protein endocytosis and 
recycling (Harel, Mattson, & Yao, 2011). The function of PICALM in AD is 
perplexing. There are conflicting results on how PICALM could modulate AD 
pathology. In yeast, mice and rat models, increased PICALM has been shown to 
increase Aβ production (Treusch et al., 2011; Xiao et al., 2012).  However, in 
vitro show that increased PICALM results in decreased endocytosis of transferrin 
(Tebar et al., 1999). It has been proposed that PICALM may function in a cargo 
specific manner.  
 
Significance of the Study 
Recent advances in GWAS have provided insights into AD genetics.  
GWAS scans though the human genome for SNPs which associate with disease.  
Recent studies with large populations identified several risk genes for AD, 
including PICALM. Though these SNPs may have a modest effect, they have 
been replicated with significance numerous times in different populations.  
Although GWAS can identify genetic variant associations, there is a lack of 
functional link between the genetic variants and AD. This study aims to 
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characterize the link between PICALM genetic association with AD. PICALM is 
part of the clathrin assembly protein family and the encoded protein assists in 
clathrin coat formation in clathrin-mediated endocytosis. PICALM assists clathrin 
coat formation by scaffolding AP2 and clathrin to generate a clathrin coated pit. 
Genetic variant rs3851179, located upstream of PICALM, was associated with 
AD. In this study we hypothesize that rs3851179 is associated with PICALM 
expression or splicing. 
  
 11 
 
Figure 1.1 APP Processing.  
In the non- amyloidogenic pathway, APP is proteolytically cleaved by 
αsecretase and subsequently by γ secretase to produce soluble APP (s-APP 
αandp3, respectively. In the amyloidogenic pathway, APP is cleaved by β 
secretase and γ secretase resulting in s-APP β and Aβ fragment, respectively. 
Accumulation of Aβ fragments results in amyloidogenic plaque. 
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Figure 1.2 PICALM Exons, Protein Binding Sites and Critical Protein Motifs 
PICALM encodes protein motifs and domains important for binding to PIP2, AP2 
and clathrin. This gene schematic shows the 21 PICALM exons. N-terminus of 
PICALM binds PIP2 via the ANTH domain. ANTH domain is encode by several 
exons, diagram not to scale. Three motifs important for effective PICALM binding 
to AP2 is encoded by exons 11, 13, and 14 and c-terminus of PICALM binds to 
clathrin (Meyerholz et al., 2005).  
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Figure 1.3 PICALM Pathogenic model 
Clathrin and cargo molecules are assembled into clathrin-coated pits on the 
plasma membrane together with an adaptor protein 2 (AP2) that links clathrin with 
transmembrane receptors, concluding in the formation of mature clathrin-coated 
vesicles (CCVs). CCVs are then actively uncoated and transported to 
early/sorting endosomes. PICALM binds to PIP2 on the plasma membrane, while 
also binding with AP2 and clathrin. 
Adapted from: (Bali et al., 2010)  
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Chapter 2 
Genetics of PICALM Expression and Alzheimer’s Disease 
 
 
Abstract 
Novel Alzheimer’s disease (AD) risk factors have been identified by 
genome-wide association studies.  Elucidating the mechanism underlying these 
factors is critical to the validation process and, by identifying rate-limiting steps in 
AD risk, may yield novel therapeutic targets.  Here, we evaluated the association 
between the AD-associated polymorphism rs3851179 near PICALM, which 
encodes a clathrin-coated pit accessory protein. Immunostaining established that 
PICALM is expressed predominately in microvessels in human brain.  Consistent 
with this finding, PICALM mRNA expression correlated with expression of the 
endothelial genes vWF and CD31.  Additionally, we found that PICALM 
expression was modestly increased with the rs3851179A AD-protective allele. 
Analysis of PICALM isoforms found several isoforms lacking exons encoding 
elements previously identified as critical to PICALM function.  Increased 
expression of the common isoform lacking exon 13 was also associated with the 
rs3851179A protective allele; this association was not apparent when this 
isoform was compared with total PICALM expression, indicating that the SNP is 
associated with total PICALM expression and not this isoform per se. 
Interestingly, PICALM lacking exons 2-4 was not associated with rs3851179 but 
was associated with rs592297, which is located in exon 5. Thus, our primary 
findings are that multiple PICALM isoforms are expressed in the human brain, 
that PICALM is robustly expressed in microvessels, and that expression of total 
PICALM is modestly correlated with the AD-associated SNP rs3851179.  We 
interpret these results as suggesting that increased PICALM expression in the 
microvasculature may reduce AD risk. 
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Introduction 
Alzheimer’s disease (AD) is a devastating disease marked by cognition 
and memory decline, affecting the elderly population. Twin and family-based 
studies suggest that sporadic late onset AD risk is genetically linked 
(Avramopoulos, 2009; Gatz et al., 2006).  Recent genome wide association 
studies (GWAS) have identified loci of genetic variance, single nucleotide 
polymorphisms (SNP)s, that are associated with AD risk (Harold et al., 2009; 
Hollingworth et al., 2011; Jun et al., 2010; Lambert et al., 2009; Lambert et al., 
2011; Naj et al., 2011). Elucidating the mechanism of action of these SNPs 
validates the SNP as an AD risk factor and may identify novel AD pathways. 
Additionally, since steps in AD pathways that are modulated by genetics may be 
susceptible to pharmacologic manipulation, identifying the actions of AD-
associated SNPs may lead to robust new pharmacologic targets.  
 
One of these SNPs is near the gene PICALM (phosphatidylinositol binding 
clathrin assembly protein) which is involved in endocytosis.  The primary AD-
associated SNP is rs3851179, which lies approximately 80 kb 5’ of 
PICALM(Hollingworth et al., 2011; Morgan, 2011; Naj et al., 2011). PICALM itself 
is encoded by 21 exons, several of which are variably spliced (Flicek et al., 
2014). Here, we sought to elucidate how rs3851179 alters PICALM expression or 
splicing to modulate AD risk. We report that PICALM is expressed robustly in 
microvessels and moderately in other cell types.  Rs3851179 was modestly 
associated with total PICALM expression as well as the major PICALM isoform 
lacking exon 13.  In contrast, the expression of rare PICALM isoforms lacking 
exons 2, 2-4, or 18-19 was not associated with rs3851179. We interpret our 
results as suggesting that the PICALM is robustly expressed in microvessels and 
that the protective rs3851179A allele is associated with modestly increased 
PICALM expression. We speculate that increased microvessel PICALM reduces 
AD risk, perhaps by facilitating Aβ clearance from the brain through enhanced 
translocation across the blood brain barrier.  
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Materials and Methods 
Ethics Statement 
The work described here was performed with approval from the University 
of Kentucky Institutional Review Board. 
 
Tissue samples 
The RNA and DNA samples for this study were from de-identified AD and 
non-AD autopsy samples.  Anterior cingulate specimens were provided by the 
University of Kentucky AD Center Neuropathology Core and have been 
described previously (Ling, Bhongsatiern, Simpson, Fardo, & Estus, 2012; Malik 
et al., 2013). A total of 52 brain samples, 28 male and 24 female, were used for 
this study.  All of the non-AD individuals were cognitively intact at their last visit 
(MMSE of 27.9 ± 3.4 (mean ± SD)). AD individuals were demented (MMSE of 
12.2± 8.3).  For the AD autopsy samples, the average age at death and 
postmortem interval was 82.9 ± 6.4 years (mean  ± SD) and 3.4 ± 0.7 hrs, 
respectively.  For the non-AD samples, the average age at death and 
postmortem interval was 82.3 ± 8.7 years (mean  ± SD) and 2.8 ± 0.8 hrs, 
respectively. By NIARI neuropathology criteria, the non-AD individuals included 
21 samples with a score of no-low likelihood of AD, and 6 with intermediate.  The 
AD samples were uniformly high-likelihood of AD. RNA was prepared by the 
method of Chomczynski and Sacchi (Chomczynski & Sacchi, 1987) and 
converted to cDNA with random hexamers and Superscript II, as described 
previously (Ling et al., 2012).  Although RNA integrity analyses were not 
performed prior to reverse transcription, others have demonstrated that for qPCR 
with short amplicons, normalized expression differences are comparable 
between samples with moderate RNA degradation and those with high integrity 
RNA (Fleige & Pfaffl, 2006). 
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PICALM immunostaining 
Paraffin-embedded anterior cingulate tissue sections (5 µm thick) were 
rehydrated, underwent heat-induced antigen retrieval in citrate buffer (pH 6.0) 
and were quenched in 0.3% H2O2. Sections were immersed in 10% rabbit serum 
in Tris-buffered saline followed by an overnight incubation in anti-CALM (sc-
6433, Santa-Cruz; 1:400 dilution). After thorough rinsing in Tris-buffered saline, 
sections were incubated in biotinylated secondary antibody for 1 h, rinsed, 
incubated in ABC reagent (Vector) for 1 h, developed in Nova Red chromagen 
(Vector) and counterstained with Hematoxylin.  
 
Identification of PICALM Splice Variants in Human Brain 
Screening for PICALM splice variants was performed on a pool of cDNA 
samples from five AD and five non-AD individuals. This cDNA pool was amplified 
by PCR by using forward and reverse primers designed to produce overlapping 
products; this enabled evaluation of splicing efficiency of each internal exon 
(Table 2.1). The identity of splice variants was determined by sequencing. To 
estimate the distribution of these splice variants, exon 12-20 PCR products from 
three rs3851179 homozygous minor (A/A) and three homozygous major (G/G) 
individuals were TA-cloned (Invitrogen) and 847 random clones were sequenced. 
For this work, thirty cycles of PCR (Platinum Taq, Invitrogen) were performed by 
using primers corresponding to exons 12 and 20 (Table 2.1). PCR conditions 
were 94° for 15 seconds, 60° for 15 seconds, and 72° for 60 seconds (Veriti 96-
Well Thermal Cycler, Life Tech). PCR was conducted using approximately 30 ng 
of cDNA template. After PCR, samples were cloned into pcDNA2.1 according to 
the manufacturer’s instructions (TA-Cloning Kit, Invitrogen) and sequenced.  
 
Quantitation of PICALM Expression 
Total PICALM expression was quantified by qPCR using primers 
corresponding to sequences within the constitutively present exons 9 and 10 
(Table 2.1); PICALM isoforms lacking exon 2, exons 2-4, 13 or 18-19 were 
quantified similarly (Table 2.1). As no single Ensembl transcript incorporates 
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each of the exons that we identify here, note that our exon designations are 
derived from ENST00000393346 for exons 1-16. Exons 17-21 correspond to the 
final five exons within ENST00000532317. PCR was conducted using an initial 2-
minute incubation at 95°, followed by cycles of 10 seconds at 95°, 20 seconds at 
60°, and 20 seconds at 72°.  The 20 µL reactions contained 1µM of each primer, 
1x PerfeCTa SYBR Green Super Mix (Quanta Biosciences), and 30 ng cDNA. 
Experimental samples were amplified in parallel with serially diluted standards 
that were generated by PCR of cDNA using the indicated primers followed by 
purification and quantitation by UV absorbance. Results from samples were 
compared relative to the standard curve to calculate copy number in each 
sample.  Real time assays were performed at least twice and the average copy 
number used for data analyses. Since PICALM was expressed in microvessels, 
neurons and astrocytes, we wished to compare PICALM expression to that of 
genes specific to these cell types.  Hence, we also quantified two microvessel-
specific mRNAs, CD31 and von Willebrand Factor (vWF), neuron-specific mRNA 
SYP and astrocyte-specific GFAP. (Jackson, 2003; Sadler, 1998). The copy 
number for each mRNA was then normalized to the geometric mean of reference 
genes RPL32 and EIF4H, previously quantified in this sample set (Ling et al., 
2012; Malik et al., 2013). The linear regression statistical model used to analyze 
the data included the geometric mean of CD31 and vWF (microvessel mRNA), 
GFAP, SYP, AD status and the number of rs3851179 minor alleles (SPSS 
version 21).  
 
Results  
To begin to evaluate the role of PICALM in AD, we localized PICALM 
expression in human brain by performing immunohistochemistry. We used an 
antibody that recognizes an epitope at the extreme PICALM carboxyl terminus 
that is found in all PICALM isoforms (see below). Robust PICALM expression 
was observed in microvessels in both non-AD and AD brain sections (Figure 
2.1). Consistent with other reports, we also observed less robust PICALM 
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immunostaining in other cell types that have been identified as neurons and glia 
(Ando et al., 2013; Baig et al., 2010). 
 
To elucidate the impact of the primary AD-associated SNP rs3851179 on 
PICALM, we chose a three-tiered approach.  First, we evaluated whether a non-
synonymous PICALM SNP was in linkage disequilibrium with rs3851179.  The 
rs3851179 minor allele frequency in European Americans is 35%. According to 
the Exome Variant Server (http://evs.gs.washington.edu/EVS/), there are no non-
synonymous PICALM SNPs with a minor allele frequency above 0.2% ("Exome 
Variant Server,").  Hence, the rs3851179 association with AD is not likely to be 
explained by a non-synonymous PICALM SNP. 
 
The second tier of our approach to elucidate SNP action was to evaluate 
the extent that PICALM expression correlated with rs3851179 genotype and/or 
AD status.  To this end, total PICALM expression was quantified in 52 brain 
samples by using qPCR and primers corresponding to sequences within exons 9 
and 10 which are constitutively present (see below).  PICALM copy number was 
normalized to the geometric mean of two housekeeping genes, RPL32 and 
eIF4H (Ling et al., 2012; Malik et al., 2013). Inspection of the results supports 
that total PICALM expression correlated positively with microvessel mRNA 
expression (Figure 2.2A).  To evaluate the statistical correlation between 
PICALM expression and relevant indices, we analyzed PICALM expression 
relative to AD status, rs3851179 genotype, and several cell-type specific mRNAs. 
Linear regression analysis found an overall significant model (adjusted R2=0.46) 
with a significant correlation between PICALM and rs3851179 as well as cell type 
markers but not AD (Table 2.2). Rs3851179, GFAP and microvessel mRNA 
correlated positively with total PICALM expression, whereas SYP showed 
negative correlation. The AD-protective, minor rs3851179A allele was associated 
with increased total PICALM expression.  
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The third tier of our approach to determine possible SNP function was to 
evaluate the extent that a PICALM splice variant was associated with rs3851179 
genotype and/ or AD status. We began by identifying PICALM splice variants 
present in human brain. PCR was performed by using a series of primer pairs 
that flank PICALM internal exons, e.g., primers corresponding to exons 1 and 5 
were used to evaluate whether exons 2, 3 or 4 were variably spliced.  This study 
found that multiple PICALM exons were inefficiently spliced (Figure 2.3).  
Sequencing of the exon 1-5 amplicons found that most PICALM isoforms 
contained exons 2, 3 and 4 while apparently rare isoforms lacked exon 2 or 
exons 2- 4.  Amplifying from exon 3 to exon 9, and exon 7 to exon 12 showed 
that exons 5-11 were consistently present (Figure 2.3).  This supports the use of 
primers corresponding to exons 9 and 10 for qPCR for total PICALM.  
Amplification reactions between exons 10-21 overall found multiple PICALM 
isoforms.  These isoforms were not sufficiently resolved by polyacrylamide gel 
electrophoresis to allow sequencing of individual gel-purified products. To 
overcome this issue, PICALM from exon 12 to exon 20 was PCR-amplified, and 
the PCR products cloned and sequenced.  To gain an initial evaluation of 
whether rs3851179 may be associated with PICALM splice variants, we analyzed 
RNA from three rs3851179 G/G and three rs3851179 A/A homozygous 
individuals. This effort revealed that exons 13, 14, 18 and 19 were inefficiently 
spliced.  The most common PICALM variant lacked exon 13 and contained each 
of the other exons from 12 to 20 (Table 2.3).  Other common variants contained 
each exon from 12-20, or lacked exon 13 and the initial 15 bp of exon 15, or 
lacked both exon 13 and 18. A comparison of the abundance of each isoform in 
rs3851179G/G versus rs3851179A/A individuals did not reveal striking 
differences (Table 2.3).  Overall, we interpret these data as indicating that 
multiple PICALM exons are variably spliced.  Although these isoforms were not 
associated with rs3851179 in this semi-quantitative assay, their abundance 
warranted a more quantitative evaluation.  
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For quantitation, we initially focused on exon 13 because (i) this exon is 
commonly skipped and (ii) this exon encodes the DPF peptide motif that 
contributes to PICALM binding to AP2 (Meyerholz et al., 2005).  We quantified 
PICALM lacking exon 13 (D13-PICALM) by using qPCR primers corresponding 
to sequences within exon 11 and the exon 12- exon 14 junction (Table 2.1). D13-
PICALM correlated well with total PICALM expression and constituted about 40% 
of total transcript (Figure 2.2B). D13-PICALM expression was analyzed as a 
function of rs3851179, AD status, and several cell-type specific mRNAs. The 
expression of D13-PICALM correlated with rs3851179, AD status, as well as the 
cell-type specific mRNAs (adjusted R2 =0.54, Table 2.2).  The minor 
rs38555179A allele and the absence of AD correlated with increased D13-
PICALM expression.   
 
To evaluate whether rs3851179 was associated with D13-PICALM 
independently of the SNP association with total PICALM expression, we 
analyzed D13-PICALM expression as a function of rs3851179, AD status and 
total PICALM expression.  With this analysis, we found that D13-PICALM was 
associated with AD status and total PICALM, but not rs3851179.  Hence, D13-
PICALM expression is associated with rs3851179 only because total PICALM 
expression is associated with rs3851179.  
 
We next analyzed PICALM splice variants that lacked exons 18 and 19 
(D18-19 PICALM), noting that the PICALM carboxyl region that includes amino 
acids encoded by exon 18 and 19 is critical for PICALM function (Scotland et al., 
2012). This qPCR assay used forward and reverse primers that recognized exon 
17 and the exon 17 - exon 20 junction, respectively (Table 2.1).  We found that 
D18-19 PICALM represented 1-2% of total PICALM expression (Figure 2.2C) 
and correlated with neuronal and astrocyte content but not rs3851179 (Table 
2.2).  
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We next quantified isoforms that lack exon 2 (D2-PICALM).  This isoform 
is expected to not encode a functional protein because the loss of exon 2 
introduces a codon frameshift with a premature stop codon in exon 3. Exon 2 
encodes a portion of the ANTH domain that binds PIP2 on the plasma membrane 
during the initial stage of clathrin-coated pit formation (Dreyling et al., 1996), We 
found that D2-PICALM was typically rare, representing less than 1% of total 
PICALM expression (Figure 2.2D). However, two samples showed increased 
D2-PICALM expression, ranging as high as 3.6%.  The reason underlying the 
higher D2-PICALM in these individuals was unclear; these individuals both had 
AD, they differ in sex (one female and one male), and had a post-mortem interval 
similar to the other samples (2.4-4.0 hours).  When these outlier samples were 
excluded from analysis, D2-PICALM was significantly associated with 
microvessel and neuronal content, as well as AD status but not rs3851179 
genotype (adjusted R2=0.41, Table 2.2).  D2-PICALM was increased in AD 
individuals. 
 
We also identified a PICALM isoform lacking exons 2-4 (D2-4 PICALM).  
The D2-4 PICALM isoform was also present at low levels, with an average of 
0.28 ± 0.15% (mean ± S.E.) of total PICALM expression (Figure 2.2E).  
Expression of D2-4 PICALM was associated with AD but not with rs3851179 or 
microvessel content, suggesting that this variant is not expressed in microvessels 
(Table 2.2). Interestingly, Schnetz-Boutaud et al have reported that an exon 5 
SNP rs592297 is in linkage disequilibrium with rs3851179 (D’=1, r2=0.34) and 
proposed that rs592297 modulates the activity of an exon splicing enhancer 
(Schnetz-Boutaud et al., 2012).  Therefore we evaluated whether rs592297 was 
associated with D2-4 PICALM expression.  We found that rs592297 associated 
with the D2-4 PICALM (Figure 2.2F, Table 2.2). Hence, higher D2-4 PICALM 
expression is associated with the rs592297C minor allele.  The percentage of 
PICALM expressed as D2-4 PICALM was quite low but was increased from 0.23 
± 0.11% in rs592297 major allele homozygous samples to 0.36 ± 0.17% in 
samples with the rs592297 minor allele (Figure 2.2F, p=0.004). Although we and 
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others have not examined the association of this SNP with AD directly, based on 
the linkage between rs592297 and rs3851179, the minor rs592297C allele is 
likely to associated with increased AD risk (Schnetz-Boutaud et al., 2012). 
 
Discussion 
The primary findings of this paper are (i) multiple PICALM isoforms are 
expressed in human brain, (ii) consistent with immunohistochemistry results that 
PICALM is commonly found in microvessels, expression of total PICALM and the 
abundant D13-PICALM is positively correlated with the expression of microvessel 
mRNAs,  (iii) total PICALM expression correlates modestly with the AD-
associated SNP rs3851179, (iv) D2-4 PICALM was associated with AD status 
and an exon five SNP, rs592297, which is in linkage disequilibrium with 
rs3851179 (r2=0.34).  However, D2-4 PICALM was a rare isoform, suggesting 
that this association is not responsible for the SNP association with AD, and (v) 
two additional rare PICALM isoforms, D18-19 PICALM and D2-PICALM were 
variably associated with AD and cell-specific mRNAs. Overall, we interpret our 
results as suggesting that multiple PICALM isoforms are expressed in the brain, 
and that correcting for cell-specific mRNAs allows the discernment that the AD-
protective allele of rs3851179 is associated with increased PICALM expression. 
 
Immunostaining showed abundant PICALM expression in microvessels.  
Consistent with this observation, total PICALM expression correlated with CD31 
and vWF expression, genes highly expressed in endothelial cells (Jackson, 2003; 
Sadler, 1998).  Hence, our statistical model for PICALM expression included the 
geometric mean of these microvessel mRNAs, well as SYP and GFAP. When we 
analyzed PICALM expression in this fashion, PICALM expression correlated with 
rs3851179 genotype. Indeed, inclusion of the expression of these cell-type 
specific mRNA is the primary difference between our study which detected an 
association between PICALM expression and rs3851179 and prior studies that 
did not discern this association (Allen et al., 2012; Karch et al., 2012).  The 
modest association that we observed may reflect that rs3851179 is not a 
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functional SNP but rather is in linkage disequilibrium with SNP(s) that directly 
modulate PICALM expression. Rs3851179 is unlikely to be a directly functional 
SNP since its well removed from PICALM at 80kbp upstream and does not alter 
a transcription factor binding site as predicted by ENCODE (Rosenbloom KR, 
2012).  Hence, we speculate that another SNP, more proximal to PICALM, is the 
functional SNP and is in moderate linkage disequilibrium with rs3851179. 
 
Variation in PICALM expression associated with rs3851179 genotype may 
have several effects.  At the cellular level, PICALM mediates clathrin-coated-pit 
endocytosis; the amino-terminus of PICALM binds phosphatidyl-inositol 4,5 
bisphosphate (PIP2), while the central portion binds adaptor protein-2 (AP-2) and 
the carboxyl terminus binds clathrin (Meyerholz et al., 2005; Ramanan et al., 
2011a). Reducing PICALM expression by siRNA leads to altered size and shape 
of the clathrin-coated pit (Meyerholz et al., 2005; Tebar et al., 1999). Since the 
AD-protective allele of rs3851179 correlates with increased PICALM expression, 
we considered several mechanisms whereby PICALM may modulate AD risk.  
First, PICALM expression modulates APP metabolism in vitro. Decreased 
PICALM expression leads to increased APP at the cell surface while increased 
PICALM expression leads to increased APP internalization. Since APP is 
metabolized in a non-amyloidogenic pathway at the cell surface but in an 
amyloidogenic pathway in endosomes, the effects of PICALM on APP 
localization lead to altered Aβ levels: PICALM knockdown reduces Aβ while 
PICALM overexpression increases Aβ (Xiao et al., 2012). This pathway is not 
consistent with our finding that the protective rs3851179 allele increases PICALM 
expression.  
 A second pathway whereby altered PICALM may alter AD risk recognizes 
that altered PICALM expression modulates cell surface proteins in a protein-
specific fashion. For example, decreased PICALM leads to increased GluR2 
which may promote excitotoxicity (Harel et al., 2011); the protective rs3851179 
allele that increases PICALM expression may reduce AD risk by reducing 
excitotoxicity.  Increased PICALM also leads to increased cell surface transferrin 
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and EGFR (Harel et al., 2011; Huang, Khvorova, Marshall, & Sorkin, 2004; 
Meyerholz et al., 2005; Tebar et al., 1999). Consistent with a critical role for 
PICALM in iron homeostasis, PICALM-deficient mice suffer from severe anemia 
and poor erythroid development and, at the cellular level, show reduced 
transferrin uptake; iron supplementation ameliorates some aspects of PICALM 
deletion (Scotland et al., 2012). Recognizing that PICALM was robustly 
expressed in microvessels and that PICALM expression correlated positively with 
microvessel mRNAs, we speculate that increased PICALM may be AD-protective 
by facilitating Aβ clearance across the blood brain barrier (Sagare, Bell, & 
Zlokovic, 2012). Overall, altered PICALM levels may modulate AD risk by 
multiple mechanisms and is the subject of ongoing investigation. 
 
 Multiple PICALM exons were spliced inefficiently in human brain.  
Isoforms lacking many of these exons are likely to encode PICALM with altered 
function.  Isoforms lacking exon 13 were especially common.  Since a critical AP-
2 binding DPF peptide motif is encoded by exon 13, the loss of exon 13 is 
expected to reduce AP-2 binding (Meyerholz et al., 2005). Loss of this DPF motif 
may be compensated by the DIF and/or FESVF motifs encoded within exons 12 
and 14, respectively (Meyerholz et al., 2005). Isoforms lacking exons 13 and 14 
were also detected that would lack both the DPF and FESVF motifs and would 
be expected to have particularly low AP-2 binding.  Rare isoforms also showed 
an absence of exons 2 or 2-4. Since exon 2 is 143 bp, isoforms lacking exon 2 
undergo a codon frameshift such that D2-PICALM and D2-4-PICALM are 
predicted to encode only an amino terminal PICALM fragment. Since the exon 5 
SNP, rs592297, was associated with exon 2 splicing, we sought to evaluate 
whether this SNP was associated with AD.  Although rs592297 was not available 
in data from Naj et al, rs1237230 is highly linked with rs592297 (r2=0.95 in 
Europeans, (http://www.broadinstitute.org/mpg/snap/ldsearch.php) and is present 
in this dataset.  Rs1237230 was modestly associated with AD (p=0.018), relative 
to rs3851179 (p=0.00015) (Naj et al., 2011).  Hence, rs592297 does not appear 
to be robustly associated with AD risk relative to the primary PICALM SNP.  
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Although rs592297 may be a functional SNP in modulating exon 2-4 splicing, the 
modest proportion of PICALM present in this isoform may mitigate the SNP 
effects on overall PICALM function.  
 
Conclusion 
 In summary, our primary findings are that multiple PICALM isoforms are 
expressed in human brain, with prominent presence in microvessels, and that 
overall PICALM expression is correlated with the AD SNP rs3851179.   Rare 
PICALM isoforms are associated with AD status and / or rs592297, a SNP that is 
in moderate linkage disequilibrium with rs3851179. The rarity of these isoforms 
and their lack of association with rs3851179 suggest they are unlikely to 
contribute to AD risk. Since D13-PICALM is the most abundant PICALM isoform, 
future studies of PICALM function may wish to evaluate this isoform. 
 
Acknowledgements: Parts of this chapter have previously published in Parikh, 
Fardo, & Estus, 2014 
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Figure 2.1 PICALM immunohistochemistry in human brain.   
 
Human anterior cingulate was immunostained with anti-CALM antibody, 
revealing robust microvessel labeling (bar=100µm).  
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Figure 2.2 Quantitative analysis of PICALM isoform expression.   
 
The indicated mRNAs or isoforms was quantified by qPCR and compared 
relative to the AD-associated SNP rs3851179 (A-E) or rs592297, an exon 5 SNP 
(F).   
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Figure 2.3 PICALM splice patterns in human brain.   
 
PCR amplification across the indicated exons was performed on cDNA pooled 
from AD and non-AD brain samples. The products were separated by 
polyacrylamide gel electrophoresis and visualized by SYBR-Gold fluorescence. 
Single PCR products from amplifications between exon 3-9 and 7-12 indicate 
that individual exons between 5-11 are included with high efficiency.  The 
presence of multiple products in other lanes represents inefficiently spliced exons 
as confirmed in Table 2.3.  
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Table 2.1 PCR Primers. 
 
Target Name  Sequence (5'-3') 
Exons 1-5 1F Sense CTGACGGACCGAATCACTG 
 5R Antisense TCAAGAAGTGCATCCATCTGA 
Exons 3-9 3F Sense TGGCTTCAAGAAACACGTTG 
 9R Antisense GCTTGCAGCTGTAGAATCTTTG 
Exons 7-12 7F Sense TGAAAAAGAACCAATGCAAAGA 
 12R Antisense CCCCATGTACTTGCTACCTGA 
Exons 10-14 10F Sense CTTTCCAATGCAGTGTCTTCC 
 14R Antisense CCCCAGAATCTACTACAATAACATTTG 
Exons 12-17 12F Sense GCCCAATGATCTGCTTGATT 
 17R Antisense CATTGTTGCAGCATTCCAAG 
Exons 15-20 15F Sense GCTTTGATGAACTAGGTGGACTT 
 20R Antisense GCAGTTTGGATTTTGCTGGA 
Total PICALM 9 Sense ACAGGCCCCTAGCAGTCTTC 
 10 Antisense TGCTTTTCCCTTTCATCCAC  
D13 11 Sense TGCAGCCTCTCCTGTATCCACCT 
 12-14 Junction Antisense GGAGAAGGAGTGAATCCTCCC 
D18-19 17 Sense TGGAGTCAACCAGGTGAAAA 
 17-20 Junction Antisense CATTTGTGGAGGCATTGTTG 
D2 1 Sense GAGGAGCTGCAGAGATGTCC 
 1-3 Junction Antisense TACTGAATAAAACGAGTCCAGGTG 
D2-4 1-5 Junction Sense AAAGCACCTGGACTGGCTGA 
 6 Antisense GGCAGCATTTATTACCCCATT 
CD31 CD31F Sense ATTGCAGTGGTTATCATCGGAGT 
 CD31R Antisense CTCGTTGTTGGAGTTCAGAAGTGG 
VWF vWF F Sense CGGCTTGCACCATTCAGCTA 
 vWF R Antisense TGCAGAAGTGAGTATCACAGCCATC 
Exon12-20 12 Sense GCCCAATGATCTGCTTGATT 
 20 Antisense TTGGTTGCGTCATTACAGGA 
GFAP Ex 4  Sense AAGAGATCCGCACGCAGTAT 
 Ex 5 Antisense GTAGTCGTTGGCTTCGTGCT 
SYN SYN F Sense AGGGAACACATGCAAGGAG 
 SYN R Antisense CCTTAAACACGAACCACAGG 
 
PCR primers used for screening splice variants, cloning, qPCR and sequencing.   
  
 32 
Table 2.2 Multivariate Linear Regression Analysis of Total PICALM and 
Isoforms.  
  Standardized  
β Coefficients 
p-value 
  Model: Total PICALM Expression 
(Adj r2=0.46) 
 
  AD Status -0.05 0.66 
  Rs3851179 0.298 6.9 x 10-3 
  Microvessel mRNA 0.387 8.6 x 10-4 
  SYP mRNA -0.455 1.2 x 10-4 
  GFAP mRNA 0.313 0.01 
      
  Model: D13-PICALM (Adj  r2=0.54)  
  AD Status -0.304 4.9 x 10-3 
  Rs3851179 0.268 8.1 x 10-3 
  Microvessel mRNA 0.302 4.0 x 10-3 
  SYP mRNA -0.519 4.2 x 10-6 
  GFAP mRNA 0.513 1.8 x 10-5 
      
  Model: D18-19 PICALM (Adj  r2=0.21)  
  AD Status 0.011 0.94 
  Rs3851179 -0.036 0.78 
  Microvessel mRNA 0.255 0.06 
  SYP mRNA -0.36 8.0 x 10-3 
  GFAP mRNA 0.312 0.03 
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 Table 2.2, continued.  
 
 
  Model: D2-PICALM (Adj r2=0.41)  
  AD Status 0.238 0.05 
  Rs3851179 0.084 0.46 
  Microvessel mRNA 0.287 0.02 
  SYP mRNA -0.429 1.0 x 10-3 
  GFAP mRNA 0.24 0.06 
      
  Model: D2-4 PICALM (Adj r2=0.10)  
  AD Status -0.322 0.03 
  Rs3851179 0.114 0.40 
  Microvessel mRNA 0.002 0.99 
  SYP mRNA 0.233 0.10 
  GFAP mRNA -0.041 0.79 
      
  Model: D2-4 PICALM (Adj r2=0.24)  
  AD Status -0.245 0.08 
  Rs592297 0.384 4.0 x 10-3 
  Microvessel mRNA 0.004 0.97 
  SYP mRNA 0.243 0.06 
  GFAP mRNA 0.001 0.99 
 
Total PICALM, D13-PICALM, D18-19 PICALM, D2-PICALM, and D2-4 PICALM 
expression was analyzed as a function of AD, rs3851179 and microvessel 
mRNA, SYP and GFAP content by using a linear regression model. D2-4 
PICALM was also analyzed as a function of rs592297, along with AD, 
microvessel mRNA, SYP and GFAP. Adj: Adjusted 
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Table 2.3 Semi-Quantitative PICALM Isoform Analysis.  
 
 Rs3851179 Genotype 
PICALM Isoforms (exons 12-20) AA 
(%Total Clones) 
GG 
(%Total Clones) 
D13 45.4 ± 5.3 44.0 ± 9.0 
D13, 14 1.9 ± 1.6 1.7 ± 1.6 
Dp15 1.8 ± 2.2 4.5 ± 4.4 
D13, p15 15.3 ± 0.5 16.4 ± 3.2 
D13, 18 9.2 ± 4.3 9.3 ± 1.5 
D13, p15, 18 5.9 ± 1.8 4.2 ± 0.7 
D18 2.8 ± 2.1 3.1 ± 1.8 
D13, 18, 19 2.6 ± 2.6 0.9 ± 0.4 
D13, p15, 18, 19 3.7 ± 3.3 0.4 ± 0.4 
Full Length (12-20) 7.2 ± 3.0 12.6 ± 6.5 
 
Complementary DNA from three rs3851179A/A and three G/G samples was 
amplified and the PCR amplicons cloned.  A total of 847 random clones were 
then sequenced. This table shows the frequencies of each isoform (mean ± SD), 
noting that “D” indicates that an exon is missing while “p” designates a partial 
exon deletion, i.e., p15 refers to clones lacking first 15 bp of exon 15.  Additional 
isoforms with an average frequency of less than 1% are not included, including 
rare isoforms that lacked the first 21 bp of exon 13. 
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Chapter 3 
An Intronic PICALM Polymorphism, rs588076, is Associated with Allelic 
Expression of a PICALM Isoform 
Abstract 
 Although genome wide studies have associated single nucleotide 
polymorphisms (SNP)s near PICALM with Alzheimer´s disease (AD), the 
mechanism underlying this association is unclear. PICALM is involved in clathrin-
mediated endocytosis and modulates Aβ clearance in vitro. Comparing allelic 
expression provides the means to detect cis-acting regulatory polymorphisms. 
Thus, we evaluated whether PICALM showed allele expression imbalance (AEI) 
and whether this imbalance was associated with the AD-associated 
polymorphism, rs3851179.   
  We measured PICALM allelic expression in 42 human brain samples by 
using next-generation sequencing. Overall, PICALM demonstrated equal allelic 
expression with no detectable influence by rs3851179. A single sample 
demonstrated robust global PICALM allelic expression imbalance (AEI), i.e., 
each of the measured isoforms showed AEI. Moreover, the PICALM isoform 
lacking exons 18 and 19 (D18-19 PICALM) showed significant AEI in a subset of 
individuals. Sequencing these individuals and subsequent genotyping revealed 
that rs588076, located in PICALM intron 17, was robustly associated with this 
imbalance in D18-19 PICALM allelic expression (p=9.54 x 10-5). This 
polymorphism has been associated previously with systolic blood pressure 
response to calcium channel blocking agents.  To evaluate whether this 
polymorphism was associated with AD, we genotyped 3269 individuals and 
found that rs588076 was modestly associated with AD.  However, when both the 
primary AD SNP rs3851179 was added to the logistic regression model, only 
rs3851179 was significantly associated with AD.  
 PICALM expression shows no evidence of AEI associated with 
rs3851179. Robust global AEI was detected in one sample, suggesting the 
existence of a rare SNP that strongly modulates PICALM expression. AEI was 
detected for the D18-19 PICALM isoform, and rs588076 was associated with this 
 36 
AEI pattern.  Conditional on rs3851179, rs588076 was not associated with AD 
risk, suggesting that D18-19 PICALM is not critical in AD. In summary, this 
analysis of PICALM allelic expression provides novel insights into the genetics of 
PICALM expression and AD risk. 
 
Introduction 
Phosphatidylinositol binding clathrin assembly protein (PICALM) facilitates 
clathrin-mediated endocytosis. PICALM binds phosphatidylinositol 4,5- 
bisphosphate (PIP2), adaptor protein 2 (AP2) and clathrin to mediate endocytic 
clathrin coated vesicle formation at the plasma membrane. Although PICALM is 
ubiquitously expressed, PICALM expression is more pronounced in microvessels 
(Baig et al., 2010; Parikh, Fardo, et al., 2014). Previous studies have shown 
PICALM co-localizes with APP and modulates amyloid beta (Aβ) generation 
(D'Angelo et al., 2013; Kanatsu et al., 2014; Xiao et al., 2012).  Accumulation of 
Aβ deposits is a hallmark of Alzheimer’s Disease (AD) pathology. 
 
Genome wide association studies in multiple cohorts have identified single 
nucleotide polymorphisms (SNP)s near the PICALM gene as significantly 
associated with AD risk (Harold et al., 2009; Jun et al., 2010; Lambert et al., 
2009; Pedraza et al., 2014; Seshadri et al., 2010). Studies were first conducted 
with Caucasian populations and then independently verified in several although 
not all Asian populations (Chen et al., 2012; Li et al., 2011; G. Liu et al., 2013; 
Miyashita et al., 2013; Yu et al., 2011). These studies report that the rs3851179 
A allele reduces AD risk with an odds ratio of 0.88 (Harold et al., 2009). This SNP 
is located approximately 80kb 5’ of PICALM.  
 
Understanding how rs3851179 alters PICALM to impact AD risk may lead 
to novel insights into AD mechanisms and potential treatments.  Since rs3851179 
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is not in linkage disequilibrium (LD) with a SNP that alters a PICALM amino acid 
(r2<0.1), we hypothesize that rs3851179 is associated with changes in mRNA 
transcription or processing. Allelic expression imbalance (AEI) which is an 
expression difference between allelic transcripts within an individual, has been 
used to detect cis-regulatory effects (Jentarra, Rice, Olfers, Saffen, & Narayanan, 
2011; Jones & Swallow, 2011; Mondal, Sharma, Elbein, & Das, 2013; Pham et 
al., 2012; Smith et al., 2013).  
 
Here, we performed an AEI analysis by comparing allelic expression 
through the use of two exonic SNPs, rs76719109 and rs592297, in AD and non-
AD brain samples.  These studies included 35 samples that were heterozygous 
for rs76719109 and 19 samples that were heterozygous for rs592297.  While 
PICALM expression did not show AEI overall, one individual showed robust 
PICALM AEI, with an allelic ratio of 0.76.  Additionally, significant AEI was 
detected for the PICALM isoform lacking exons 18 and 19 (D18-19 PICALM). 
Sequencing and additional genotyping established that rs588076 was robustly 
associated with this AEI pattern. Interestingly, rs588076 has been associated 
with blood pressure response to Ca++ channel blocking agents (Kamide et al., 
2013).  We discuss these overall results in the context that genetic regulation of 
PICALM isoforms relative to AD risk is highly complex with further work 
necessary to elucidate the mechanisms modulating genetic risk.  
 
Materials and Methods 
DNA and RNA extraction from human brain tissue 
The RNA and DNA samples for this study were from de-identified AD and 
non-AD human brain anterior cingulate specimens provided by the University of 
Kentucky AD Center Neuropathology Core and have been described previously 
(Ling et al., 2012; Malik et al., 2013; Parikh, Fardo, et al., 2014). The overall 
dataset included 30 AD samples (14 male, 16 female) and 30 non-AD samples 
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(15 male, 15 female). The age at death for individuals that were cognitively intact, 
i.e., non-AD, was 82 ± 8 years (mean ± SD, n = 30) while age at death for AD 
individuals was 82 ± 6 (n = 30). The average post-mortem interval (PMI) for non-
AD individuals was 2.8 ± 0.9 hours (mean ± SD, n = 30) while the PMI for AD 
individuals was similar at 3.4 ± 0.6 hours (n = 30). For the rs76719109 AEI 
assay, a subset of 35 samples were heterozygous for this SNP and included 18 
non-AD (9 male, 9 female) and 17 AD (9 male, 8 female) (Table 3.1, 3.2). For the 
rs592297 AEI assay, a total of 19 out of 60 samples were heterozygous, 13 non-
AD (7 male, 6 female) and 6 AD (3 male, 3 female) (Table 3.3, 3.4). Preparation 
of gDNA, RNA and cDNA was performed as described in previous studies (Ling 
et al., 2012; Malik et al., 2013; Parikh, Fardo, et al., 2014). Although RNA 
integrity analyses were not performed prior to reverse transcription, others have 
demonstrated that for qPCR with short amplicons, normalized expression 
differences are comparable between samples with moderate RNA degradation 
and those with high integrity RNA (Fleige & Pfaffl, 2006).  We recognize that the 
absence of RNA integrity analysis constitutes a caveat of this study. 
 
Genotyping and sequencing  
DNA samples were genotyped for rs3851179, rs76719109, rs592297 and 
rs588076 by using unlabeled PCR primers and two allele-specific TaqMan FAM 
and VIC dye-labeled MGB probes (Pre-designed TaqMan SNP Genotyping 
Assay, Applied Biosystems) on a real-time PCR machine (Chromo4, MJ 
Research PTC-200).  
 
Allelic imbalance assay 
Rs76719109 is in exon 17.  For AEI analysis with rs76719109, PICALM 
was amplified from exon 17 to exon 20 for cDNA and exon 17 to intron 17 for 
genomic DNA.  For rs592297, PICALM was amplified from exon 5 to exon 6 for 
cDNA and exon 5 to intron 5 for genomic DNA. Exon numbering is according to 
PICALM-005 ENST00000393346 for exons 1-16 and exons 17-21 correspond to 
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the final five exons within PICALM-002 ENST00000532317 in Ensembl, since no 
single ENSEMBL transcript includes each of the exons the we identify here (Paul 
Flicek). The PCR primers included Ion Torrent adapters, individual barcodes and 
DNA sequence flanking the region of interest (Table 3.5). Each PCR reaction 
(50uL) contained 1x PCR buffer, 20ng cDNA or 100 ng gDNA, 1uM of forward 
and reverse primer, 0.1mM dNTP and 0.5 Units Taq (Platinium Taq, Invitrogen).  
Cycles consisted of pre-incubation at 95˚C for 2 minutes, followed by 28 cycles of 
95˚C for 15 s, 60˚C for 30s and 72˚C for 60s followed by incubation at 75˚C for 7 
minutes. To acquire equal representation from each sample, relative amounts of 
PCR product were quantified by subjecting 10 uL of PCR product to 
electrophoresis on 7.5% polyacrylamide gels and SYBR gold staining relative to 
a Low DNA Mass Ladder (Invitrogen). Approximately 2 ng of each individual’s 
cDNA and gDNA PCR products were pooled, purified using Agencourt AMPure 
XP and subjected to Ion Torrent sequencing on a Ion Torrent 316 chip (Ion PGM 
Sequencer).  
 
Data extraction and analysis of allelic mRNA expression 
Allelic counts were extracted from DNA sequences by using Perlscript in a 
three-step fashion: (i) sequences corresponding to each sample were separated 
based on their barcode, (ii) gDNA and cDNA were then separated based on the 
presence of intronic and exonic sequences, respectively, and (iii) allele counts 
were obtained by using sequences that bridged the SNP of interest.  
 
Standard curve generation 
One rs76719109 homozygous major (GG) and one homozygous minor 
(TT) individual was selected based on similar qPCR copy numbers. Five dilutions 
were prepared with different ratios of each individual’s cDNA: 1:4, 1:2, 1:1, 2:1, 
and 4:1. These samples were PCR amplified and subjected to sequencing as 
described above. 
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Statistical analysis 
Analysis of allelic counts was based upon the assumption that transcript 
read counts follow a Poisson distribution (H. Jiang & Wong, 2009).  As such, 
each allele from the heterozygous SNP was used to define two random 
variables.  Following the rs76719109 example of a G/T SNP, we denote the pair 
of transcript counts as 𝐺 ~ 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 (𝜆𝐺) and 𝑇 ~ 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 (𝜆𝑇).  That is, G and T 
are Poisson-distributed random variables with means 𝜆𝐺 and 𝜆𝑇, respectively. It 
can then be readily shown that for a given pair of realized transcripts counts, G=g 
and T=t, the transcript count of either allele is binomially distributed with success 
probability equal to a ratio of component means.  That is, 𝐺 | 𝐺 + 𝑇 = 𝑔 +
𝑡 ~ 𝐵𝑃𝑃 (𝑔 + 𝑡,𝑝 = 𝜆𝐺
𝜆𝐺+𝜆𝑇
). Testing for AEI then simplifies to an examination of the 
null hypothesis that the pair of transcript counts comes from the same 
distribution, i.e., that 𝜆𝐺 = 𝜆𝑇, which is equivalent to testing 𝐻0: 𝑝 = 12  [𝐺 | 𝐺 + 𝑇 =
𝑔 + 𝑡 ~ 𝐵𝑃𝑃 (𝑔 + 𝑡, 1
2
)]. This null hypothesis agrees with the intuition that when the 
total of transcript counts is known, the number generated from a specific allele is 
essentially a sequence of independent, equally probable trials.  Thus, rejection of 
this null hypothesis corresponds to AEI. 
 
Measuring transcripts from genomic DNA is one way of correcting for the 
possibility of differential experimental error between allele transcript counts. 
Conceptually, one could adapt methods for determining AEI by an appropriate 
adjustment with the ratio of reads from gDNA as these reads should theoretically 
come from the same distribution regardless of AEI (Fardo et al., unpublished). 
Alternatively, it can be assumed that one allele is derived from a distribution with 
an inflated mean solely due to experimental error (i.e., under the null hypothesis 
of no AEI).  In this case, we have that the means of the transcript reads satisfy 
either 𝜆𝐺 = (1 + 𝛿)𝜆𝑇 or (1 + 𝛿)𝜆𝐺 = 𝜆𝑇.  Here, the probability parameter, p, for 
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the count probability in the AEI test becomes 1+𝛿
2+𝛿
 or 1
2+𝛿
, respectively. For our 
gDNA data, we have a maximum 8.5% increase of one allele over the other and 
chose to conservatively assume a 20% mean increase (i.e., 𝛿 = 0.2). We then 
calculate the AEI test p-value from the lesser-significant test of 𝐻0: 𝑝 = 1+𝛿2+𝛿 and 
𝑝 = 1
2+𝛿
. 
 
Genotype association with AD risk  
The Mayo Clinic dataset has been described previously (Naj et al., 2011; 
Ridge, Mukherjee, Crane, Kauwe, & Alzheimer's Disease Genetics, 2013).  
Briefly, the Mayo Clinic dataset contained 1789 cases and 2529 non-ADs 
collected from six centers from the US and Europe as described (Naj et al., 
2011). Direct genotyping of rs3851179 and rs588076 was performed using a 
TaqMan SNP genotyping assay in an ABI PRISM 7900HT Sequence Detection 
System with 384-well block module from Applied Biosystems (California, USA). 
First-pass genotype cluster calling was analyzed using the SDS software version 
2.2.3 (Applied Biosystems, California, USA). Variants passed Hardy-Weinburg 
(P>0.05) and minor allele frequencies are consistent with public databases (EVS, 
HapMap, 1000G). Association testing for rs3851179, with and without rs588076, 
was carried out in PLINK (Purcell et al., 2007) by using an additive logistic 
regression model corrected for appropriate covariates; diagnosis age, APOE ɛ4, 
APOE ɛ2, sex and contributing center.  
 
Results 
To detect the presence of regulatory cis-acting SNPs in human brain 
samples, we measured allelic ratios in cDNA from reverse transcribed mRNA. 
Heterozygosity for an exonic “reporter” SNP provides the means to compare the 
expression of one allele with another allele within an individual. Our criteria for 
reporter SNPs for AEI analysis is that the SNPs are present in exons and have a 
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minor allele frequency (MAF) greater than 15%, which allows for sufficient 
sample numbers for analysis.  Only two PICALM SNPs satisfied these criteria, 
rs76719109 and rs592297 (Figure 3.1). Rs76719109 has a MAF of 0.44 and 
resides within exon 17; PCR amplification from exon 17-20 allowed us to 
measure AEI for total PICALM as well as PICALM splice variants lacking exon 18 
or exons 18-19 (Figure 3.1a).  Rs592297 has a MAF of 0.20 and resides in exon 
5.  PCR amplification from exon 5-6 produced a single PCR product for cDNA 
(Figure 3.1b).  The AEI assay was validated in two ways.  First, we tested the 
linearity of the assay by generating a cDNA standard curve consisting of five 
different rs76719109 T:G ratios (Figure 3.2). Our input T:G ratios ranged from 
1:4 to 4:1.  We found a robust linear relationship between input and observed 
T:G ratios. Second, we applied our experimental approach to gDNA, which 
represented a positive control with an expected “allelic” ratio of 1.0. Rs76719109 
and rs592297 showed gDNA ratios of 1.01 ± 0.03 (mean ± SD, n=35) and 0.96 ± 
0.05 (mean ± SD, n=19), respectively (Figure 3.3). Hence, this AEI assay 
appears robust for detecting and quantifying variations in allelic expression.  
 
To evaluate whether the AD-associated SNP rs3851179 was associated 
with unequal allelic PICALM expression, we performed AEI analysis with 
rs76719109 and rs592297on a total of 54 samples.  Twelve of these 54 samples 
were heterozygous for both SNPs.  Hence, we analyzed PICALM for AEI in a 
total of 42 unique individual samples. This effort analyzed 4.2 million sequences 
for rs76719109 and 1.4 million sequences for rs592297. If rs3851179 modulated 
total PICALM expression, we expected to see significant AEI in individuals 
heterozygous for rs3851179, but not in individuals homozygous for rs3851179. 
When we analyzed the results for the exon 17 SNP, rs76719109, significant AEI 
was observed in only a single sample, termed AD40 (see below).  To evaluate 
whether a subtle difference in allelic expression may be present and associated 
with rs3851179, we compared the mean allelic expression between the 
rs3851179 homozygous and heterozygous groups.  This approach did not 
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discern a significant difference between the two groups, i.e., the allelic ratios for 
rs3851179 homozygous and heterozygous groups was 0.94 ± 0.08 (n=17) and 
0.97 ± 0.06 (n=18), respectively (Figure 3.4a, p= 0.24, t-test). Hence, rs3851179 
did not appear associated with PICALM AEI.  To confirm this finding and extend 
the analysis to additional samples, we analyzed allelic expression by using the 
exon 5 SNP, rs592297. Significant AEI was not observed in any sample, noting 
that the sample with the significant AEI result from the rs76719109 analysis was 
homozygous for rs592297 and not suitable for evaluation.  When the allelic ratios 
were analyzed by t-test to evaluate whether rs3851179 was associated with 
allelic expression, the findings confirmed that rs3851179 was not associated with 
robust AEI; the allelic ratios were 0.93 ± 0.05 (n= 4) for rs3851179 homozygotes 
and 1.01 ± 0.07 (n= 15) for heterozygotes (Figure 3.4b, p= 0.06).  Hence, we 
found that the total PICALM allelic ratio for each person was remarkably 
consistent with both reporter SNPs; rs3851179 is not associated with overall 
allelic PICALM expression.  
 
Interestingly, cDNA from the individual termed AD40 showed significant 
unequal allelic mRNA expression with a T:G ratio of 0.76 (Figure 3.4a, Table 
3.6).  This ratio is based on a total of four experiments that detected a total of 
68141 copies of the T allele and 88400 copies of the G allele.  This AEI was not 
due to genomic normalization as the genomic T:G ratio was 1.01. These data are 
based upon the rs76719109 SNP because this individual was homozygous for 
rs592297. A similar result was obtained when each of four separate replicates 
were analyzed individually, i.e., when each replicate was analyzed individually, 
the T:G ratio was 0.73 ± 0.04 (mean ± SD).  Hence, significant AEI was observed 
in a single individual among the 42 unique samples.  
 
Having considered overall PICALM allelic expression, we proceeded to 
apply this AEI analysis to PICALM isoforms.  The exon 17 to exon 20 PCR 
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amplicons captured three different PICALM isoforms because exons 18 and 19 
are variably spliced. These isoforms were termed full length PICALM (contains 
exons 18-19), D18-PICALM (lacked exon 18) or D18-19 PICALM (lacked both 
exons 18 and 19). We analyzed each of these isoforms for the presence of AEI 
as a function of rs3851179 heterozygosity. For the full length PICALM and D18-
PICALM isoforms, significant AEI was observed only in the AD40 sample.  To 
evaluate whether a subtle difference in allelic expression may be present, we 
compared the allelic expression of the full length PICALM isoform between the 
rs3851179 homozygous and heterozygous groups by using a t-test.  However, 
no difference was observed as the average T:G ratio in the rs3851179 
homozygous and heterozygous groups was 0.93 ± 0.07 (n=17) and 0.93 ± 0.06 
(n=18), respectively (Figure 3.5a, p= 0.81).  Likewise, for the D18-PICALM 
isoform, the rs3851179 homozygous and heterozygous groups showed mean 
T:G ratios of 0.95 ± 0.09 (n=17) and 1.01 ± 0.12 (n=18), respectively (Figure 
3.5b, p=value= 0.13).  When we evaluated the D18-19 PICALM isoform, 
significant AEI was detected in multiple samples (Figure 3.5c).  We analyzed 
these results in two ways.  First, we compared the frequency of samples with 
significant AEI between the rs3851179 homozygous and heterozygous 
individuals by using a Fisher’s exact test; a significant difference between groups 
was not detected (Figure 3.5c, p= 0.44).  Second, we compared the mean T:G 
ratio between rs3851179 homozygous and heterozygous individuals by using a t-
test.  However, the rs3851179 homozygous and heterozygous individuals 
showed similar values that did not achieve significance , i.e., 1.19 ± 0.16 and 
1.11 ±  0.22, respectively (p=0.08). Hence, rs3851179 heterozygosity was not 
associated with AEI for these PICALM isoforms. 
 
We considered the subset of samples that showed significant AEI further.  
Among these, AD40 showed significant AEI for each of the isoforms, with the 
D18, D18-19 and full length PICALM isoforms having allelic T:G ratios of 0.77, 
0.53 and 0.77, respectively. As noted above, this finding is consistent with the 
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hypothesis that a rare SNP acts to alter global PICALM allelic expression in this 
individual.  Additionally, we noted that the D18-19 PICALM isoform showed 
significant AEI for multiple individuals (Figure 3.5c). In these eight individuals, 
the rs76719109T allele was expressed more than the G allele with the ratio 
ranging from 1.30 to 1.48 (Table 3.7).  This is in contrast to AD40 where the T 
allele was expressed less than G allele at a ratio of 0.53 (Table 3.6, 3.7).  
 
Since the D18-19 PICALM isoform but not overall PICALM showed AEI in 
multiple samples, we hypothesized that a local SNP influences this splice 
pattern.  To identify this SNP, we sequenced 6400 bp of genomic DNA between 
exons 17-20 in C11 and AD33, the two individuals showing the highest AEI ratio 
(Table 3.1). We identified several SNPs that were heterozygous in these samples 
including rs588076, rs645299, and rs618629. The MAF for these SNPs in CEU 
range from 20-31% (Table 3.8). Additionally, these SNPs are in strong LD with 
each other (Table 3.8).  Rs588076 and rs618629 reside in intron 17 while 
rs645299 is within intron 18.  We genotyped all samples for rs588076. The 
frequency of samples showing significant AEI was significantly associated with 
rs588076 heterozygosity (Figure 3.5d, p=9.54 x 10-5, Fisher’s exact test).  We 
interpret these results as strongly suggesting that rs588076, or a SNP in strong 
LD with rs588076, is functional by modulating PICALM exon 18-19 splicing.   
 
Since rs588076 is associated with D18-19 PICALM AEI and rs3851179 
has been robustly associated with AD, we evaluated the extent that rs588076 is 
associated with AD risk.  We evaluated 1789 AD and 2529 non-AD individuals 
from the Mayo Clinic cohort. Rs588076 was significantly associated with AD risk 
when analyzed in a logistic regression model (odds ratio = 0.8413, 95% 
confidence intervals (0.7151-0.9898), p=0.0372). However, when rs3851179 was 
added to this logistic regression model, only rs3851179 was significantly 
associated with AD (Table 3.9).  Haplotypic analysis confirmed that the haplotype 
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containing both rs588076 and rs3851179 report the same association with AD as 
the haplotype containing only rs3851179 (data not shown). Hence, rs588076 is 
associated with D18-19 PICALM AEI but not AD risk. 
 
Discussion 
The primary findings of this report include (i) overall PICALM expression 
shows no evidence of global AEI even when parsed by AD-associated SNPs, (ii) 
robust global AEI was detected in one sample, suggesting the existence of a rare 
SNP that strongly modulates PICALM expression, and (iii) eight individuals show 
AEI for the D18-19 PICALM isoform that is associated with rs588076.  However, 
rs588076 was not associated with AD risk when considered in a model that also 
included rs3851179. In summary, analysis of allelic expression has proved a 
useful tool for the evaluation of cis-acting regulatory polymorphisms and AD risk.  
 
A consistent pattern of AEI in overall PICALM expression was not 
detected.  This was unexpected since Xu et al reported consistent and robust 
PICALM AEI (X. Xu et al., 2011). The reason for different results in these two 
studies is unclear.  The studies are similar in that both used rs76719109 as a 
reporter SNP and similar although not identical PCR primers.  The studies differ 
in that Xu et al used an Asian population while this report studied Caucasians. 
One explanation that would account for the difference in the studies was the 
presence of a confounding SNP in the Asian population in the genomic primer 
sequence because much of the AEI in Xu et al. was due to correction for 
imbalance in gDNA (X. Xu et al., 2011), although such a SNP has not yet been 
reported.   
We previously reported that the AD-associated SNP rs3851179 was 
associated with a modest difference in PICALM expression when analyzed 
relative to cell-type specific mRNAs; the minor rs3851179A allele appeared to be 
expressed modestly higher than the G allele (Parikh, Fardo, et al., 2014).  A 
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similar difference was not observed here. One possible interpretation of these 
findings is that rs3851179 or its proxy AD SNP acts in a cell-type specific fashion 
that was discernible in our analysis that included cell-type specific markers. The 
current AEI study had smaller sample size because only the samples that were 
heterozygous for rs76719019 or rs592297 were suitable for analysis. However, 
this would not be expected to affect the AEI results because they rely upon an 
intra-individual analysis. We interpret these results overall as suggesting that the 
AD-associated SNP, or its functional proxy, acts in a cell-type specific fashion to 
modulate PICALM expression. This cell-type specific action was not detectable in 
this AEI study of mRNA derived from multiple cell types.   
 
The second major finding was that robust AEI was detected for all 
PICALM isoforms in one individual, arguing for the existence of a rare functional 
SNP that strongly modulates total PICALM expression.  For this individual, the 
rs76719109G allele was consistently more abundant than the T allele for each 
PICALM isoform. We hypothesize that AD40 is unique among the 42 samples in 
showing AEI because this sample is heterozygous for a causal SNP. If this 
causal allele is present in the heterozygous state in 1 of 42 people, this SNP has 
a minor allele frequency of ~1.2%. Although current sequencing studies of the 
PICALM promoter region have not yet identified candidate functional SNPs for 
AEI in this sample, these studies are on-going and a SNP that strongly 
modulates PICALM expression would be expected to be a robust AD risk factor.  
 
The third major finding was that the D18-19 PICALM isoform showed 
robust AEI.  There was a strong skew towards increased expression of the 
rs76719109T allele. Sequencing identified several candidate SNPs including 
rs588076, which is 509 bp downstream of exon 17.  This SNP was found to be 
robustly associated with AEI for D18-19 PICALM.  There are three possible ways 
rs588076 could influence D18-19 PICALM splicing efficiency: (i) rs588076 is in 
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high LD with a functional SNP that modulates splicing, (ii) rs588076 and other 
SNPs influence D18-19 PICALM splicing in a cooperative manner, and/or (iii) 
rs588076 directly influences splicing.  Further studies are necessary to discern 
among these possibilities. 
 
The biological significance of the rs588076 association with D18-19 
PICALM is complex.  D18-19 PICALM transcripts account for 1-2% of total 
PICALM expression (Parikh, Fardo, et al., 2014). Thus rs588076 is significantly 
associated with AEI for a PICALM isoform that is relatively rare in brain. Exons 
18 and 19 encode a total of 27 amino acids that are part of the carboxyl terminal 
region required for clathrin binding and endocytosis (Scotland et al., 2012). 
Hence, the protein encoded by D18-19 PICALM is likely to have reduced function 
(Scotland et al., 2012).  However, rs588076 was not associated with AD risk and 
did not enhance the logistic regression model for the rs3851179 association with 
AD.  This leads us to conclude that the rs588076 and D18-19 PICALM isoform 
may be too rare in the brain to influence AD pathogenesis. Interestingly, 
rs588076 was recently associated with the blood pressure response to Ca++ 
channel blocking agents (Kamide et al., 2013). Since rs588076 is associated only 
with D18-19 PICALM, we speculate that this isoform may be more abundant in 
other tissues and rs588076 actions upon D18-19 PICALM mediate this systolic 
blood pressure phenotype.  
 
Conclusion 
In summary, analysis of allelic expression has shown that compelling 
PICALM AEI was not observed in most brain RNA samples. Strong global AEI 
was documented in one sample, suggesting the existence of a rare PICALM 
regulatory SNP.  A pattern of AEI was clearly discerned for the D18-19 PICALM 
isoform and rs588076 was significantly associated with this pattern. Rs588076 
was not associated with AD risk although this SNP has been associated with a 
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blood pressure-related phenotype. Allele-dependent expression studies may 
provide further insights into additional AD-associated polymorphisms.  
Acknowledgements: Parts of this chapter has previously published in Parikh, 
Medway, Younkin, Fardo, & Estus, 2014.   
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Figure 3.1 Rs76719109 and rs592297 AEI assays.  
a) For the exon 17 SNP rs76719109, a barcoded forward primer was positioned 
in exon 17, and a reverse primer was positioned in intron 17 (genomic samples) 
or exon 20 (cDNA samples). b) For the exon 5 SNP rs592297 assay, a barcoded 
forward primer was positioned in exon 5, and a reverse primer was positioned in 
intron 5 (genomic samples) or exon 6 (cDNA samples).  
 
 
 
 
 
 
 
 
 
Copyright © Ishita Jatin Parikh 2014 
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Figure 3.2 Linearity of allelic expression assay.  
Different proportions of rs76719109 T and G homozygous cDNA were mixed to 
test the linearity of the AEI assay.  The T:G ratios were 1:4, 1:2, 1:1, 2:1, and 4:1.  
An overall linear relationship was found (r2=0.99).  The slope was 0.999, i.e., the 
assay detected the T and G alleles with equal efficiency. The graphs are plotted 
log2 to avoid compression at the lower ratios and thereby better visualize the 
data (X. Xu et al., 2011). 
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Figure 3.3 Genomic DNA Allelic Ratios.  
a-b) The allelic ratio for the gDNA samples for rs76719109 and rs592297 is 
shown.  None of the samples showed significant AEI with each of the samples 
consistently near the expected 1:1 ratio (note that a 1.0 ratio is equal to 0 in log2). 
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Figure 3.4 Evaluation of total PICALM AEI with respect to rs3851179.   
a-b) Allelic PICALM expression was assessed by rs76719109 or rs592297.  Each 
individual sample was normalized to its gDNA ratio. Rs3861179 was not 
associated with significant AEI, i.e., only one sample (*) showed significant AEI.  
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Figure 3.5 Evaluation of PICALM isoform AEI with respect to rs3851179.  
The indicated PICALM isoforms were analyzed for AEI as a function of 
rs3851179 (a-c) or rs588076 (d). Each allelic ratio was normalized to the 
sample’s gDNA ratio.  a) The full length PICALM isoform contained exons 18-19 
and showed equal allelic ratios, with a non-significant trend towards an increase 
in the G allele. b) D18-PICALM showed equal allelic ratios and c) D18-19 
PICALM showed significant unequal allelic ratios in 9 samples (* p<0.05), d) The 
D18-19 PICALM AEI was associated with rs588076 heterozygosity. This pattern 
of significant AEI was not associated with sex, age or AD status (p>0.05). 
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Table 3.1 Rs76719019 Assay Non-AD Sample Demographics. 
 
Sample ID Age Sex PMI MMSE NIARI 
C01 105 Male 3 24 No 
C04 80 Male 3.5 28 No 
C06 66 Female 4.5 30 No 
C07 85 Male 2 30 Low likelihood 
C08 84 Female 1.5 13 
Intermediate 
likelihood 
C09 79 Male 2.25 26 Low likelihood 
C10 80 Male 3 27 No 
C11 75 Female 3.5 29 No 
C12 86 Female 2.25 30 Low likelihood 
C13 95 Male 1.75 28 No 
C17 72 Female 3.75 30 No 
C18 91 Female 4 29 No 
C19 86 Female 3.75 29 Low likelihood 
C20 81 Male 2 30 Low likelihood 
C22 82 Male 2.1 29 Low likelihood 
C24 75 Male 4 28 High likelihood 
C27 84 Female 2.5 30 
Intermediate 
likelihood 
C29 87 Female 2.41 28 
Intermediate 
likelihood 
 
Age, sex, PMI, MMSE and NIARI demographic of 18 non-AD samples in 
rs76719109 AEI assay.  
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Table 3.2 Rs76719019 Assay AD Sample Demographics. 
 
Sample ID Age Sex PMI MMSE NIARI 
AD33 79 Female 3 11.5 High likelihood 
AD37 83 Male 4 17.5 High likelihood 
AD40 81 Male 3.5 17 High likelihood 
AD42 86 Female 4.25 18 High likelihood 
AD43 77 Male 3.5 19 High likelihood 
AD44 84 Female 3.33 8 High likelihood 
AD45 73 Male 2.75 N/A N/A 
AD46 81 Male 3.75 0 High likelihood 
AD47 90 Female 2.8 4 High likelihood 
AD48 78 Male 3.75 17.5 High likelihood 
AD50 69 Male 4 4.5 Yes 
AD51 75 Female 2.33 21.5 High likelihood 
AD52 95 Male 4 7 High likelihood 
AD54 84 Female 5 18 High likelihood 
AD57 86 Female 3.25 7 High likelihood 
AD59 78 Male 3.5 11 High likelihood 
AD60 68 Female 3.25 26.5 High likelihood 
 
Age, sex, PMI, MMSE and NIARI demographic of 17 AD samples in rs76719109 
AEI assay.  
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Table 3.3 Rs592297 Assay Non-AD Sample Demographics. 
 
Sample ID Age Sex PMI MMSE NIARI 
C01 105 Male 3 24 No 
C02 92 Female 2.3 26 Low likelihood 
C08 84 Female 1.5 13 Intermediate likelihood 
C09 79 Male 2.25 26 Low likelihood 
C10 80 Male 3 27 No 
C11 75 Female 3.5 29 No 
C13 95 Male 1.75 28 No 
C15 77 Male 3.5 28 Low likelihood 
C19 86 Female 3.75 29 Low likelihood 
C20 81 Male 2 30 Low likelihood 
C23 74 Male 4 26 No 
C26 89 Female 1.75 30 Intermediate likelihood 
C27 84 Female 2.5 30 Intermediate likelihood 
 
Age, sex, PMI, MMSE and NIARI demographic of 13 non-AD samples in 
rs592297 AEI assay.  
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Table 3.4 Rs592297 Assay AD Sample Demographics. 
 
Sample ID Age Sex PMI MMSE NIARI 
AD33 79 Female 3 11.5 High likelihood 
AD43 77 Male 3.5 19 High likelihood 
AD50 69 Male 4 4.5 Yes 
AD51 75 Female 2.33 21.5 High likelihood 
AD54 84 Female 5 18 High likelihood 
AD58 90 Male 3.25 12 High likelihood 
 
Age, sex, PMI, MMSE and NIARI demographic of 6 non-AD samples in rs592297 
AEI assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Ishita Jatin Parikh 2014 
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Table 3.5 PCR Primers for Rs76719109 and Rs592297 AEI Assay.  
 
SNP Assay DNA Primer Sense Primer Sequence 
rs76719109 cDNA Sense 5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGGAGTCAACCAGGTGAAAA 
cDNA Anti-sense 5' 
CCTCTCTATGGGCAGTCGGTGATTTGGTT
GCGTCATTACAGGA 
gDNA Sense 5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGGAGTCAACCAGGTGAAAA 
gDNA Anti-sense 5' 
CCTCTCTATGGGCAGTCGGTGATAGGAGC
TTTTTCAACTCACCA 
rs592297 cDNA Sense 5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGAACACAGAAAAACTCCTAAA
AA 
cDNA Anti-sense 5' 
CCTCTCTATGGGCAGTCGGTGATGGCAGC
ATTTATTACCCCATT 
gDNA Sense 5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGAACACAGAAAAACTCCTAAA
AA 
gDNA Anti-sense 5' 
CCTCTCTATGGGCAGTCGGTGATTCTGTG
AAAACTTGAGGTTAAAAA 
 
 “xxxxx” denotes 5 nucleic acid barcode, which is unique for each individual. Note 
that gDNA and cDNA were amplified by the same barcoded forward primers.  
Genomic DNA and cDNA were differentiated by the reverse primers.  
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Table 3.6 PICALM AEI Analysis of AD40 Shows Significant Unequal 
Rs76719109t To G Allele Ratios. 
 
Rs76719109 Counts Ratio (T/G) 
mRNA ratio 
normalized 
to genomic 
ratio 
P-value 
Genomic G Allele 40357 1.01  0.89 
Genomic T Allele 40880    
mRNA G Allele 88400 0.77 0.76 6.76 x 10-58 
mRNA T Allele 68141    
     
Isoforms     
D18 G Allele 17777 0.78 0.77 3.63 x 10-09 
D18 T Allele 13909    
D18-19 G Allele 4103 0.54 0.53 1.96 x 10-65 
D18-19 T Allele 2203    
Full length G Allele 66520 0.78 0.77 1.88 x 10-30 
Full length T Allele 52029    
 
Genomic DNA analysis shows an overall equal allelic representation while mRNA 
analysis shows significant AEI.  This AEI was present in each of the three 
isoforms. 
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Table 3.7 D18-19 PICALM Shows Significant AEI in Nine Samples.  
 
Sample D18-19 T:G 
Counts 
Ratio  
(Normalized to genomic ratio) 
P-Value 
C01 2337:1793 1.30 8.66 x 10-3 
C11 13415:9508 1.47 7.91 x 10-34 
C20 745:523 1.43 2.78 x 10-3 
AD33 6136:4162 1.48 7.06 x 10-25 
AD43 1743:1321 1.31 9.47 x 10-3 
AD50 1529:1080 1.41 3.05 x 10-5 
AD51 5530:4243 1.33 5.27 x 10-5 
AD54 8893:6548 1.38 2.64 x 10-14 
AD40 2203:4103 0.53 1.96 x 10-65 
 
These D18-19 PICALM T:G allelic counts are the summation of three separate 
runs.  AD samples are designated by an AD prefix while non-AD samples are 
designated with a C prefix. 
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Table 3.8 Samples with Robust AEI are Heterozygous for Three SNPs.  
 
SNP 
MAF in 
CEU 
LD with 
rs3851179 
LD with 
rs588076 
LD with 
rs645299 
LD with 
rs618629 
rs588076 0.199 0.336 - 0.539 0.911 
rs645299 0.306 0.665 0.539 - 0.525 
rs618629 0.242 0.319 0.911 0.525 - 
 
The samples C11 and AD33 were sequenced from exon 17 through exon 20. 
The samples were heterozygous for the indicated SNPs.  These SNPs are in 
strong LD (Johnson et al., 2008) with each other  and have similar frequencies 
for the minor allele (Sherry et al., 2001). 
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Table 3.9 Logistic Regression Modeling Of Rs3851179 and/or Rs588076 
Effect(s) on AD.   
 
Model SNP Odds Ratio Confidence Interval P value 
rs588076 rs588076 0.8413 0.7151 - 0.9898 0.0372 
rs3851179 rs3851179 0.7786 0.6819 - 0.8891 0.0002 
rs3851179 + rs588076 rs3851179 0.7767 0.6604 - 0.9136 0.0023 
rs3851179 + rs588076 rs588076 1.005 0.8238 - 1.227 0.959 
 
In addition to the indicated SNPs, these models were adjusted for age of onset, 
APOE alleles, sex and contributing center. 
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Chapter 4 
Discussion and Future Studies 
 
Primary Findings 
 Recent AD GWAS have identified SNPs in several genes involved in 
receptor endocytosis. Several of these SNPs, including rs3851179, are near the 
gene phosphatidylinositol-binding clathrin assembly protein (PICALM) (Harold et 
al., 2009; Jun et al., 2010; Lambert et al., 2009; Pedraza et al., 2014; Seshadri et 
al., 2010). It is unclear how PICALM is involved in AD pathogenesis, thus a 
greater understanding of underlying molecular mechanisms of PICALM is 
needed. In this study I have characterized PICALM expression and splicing in 
human brain to help elucidate how this gene can be associated with AD. 
 
 The complexity of PICALM expression and splicing necessitated a 
complex analysis. PICALM is a ubiquitously expressed protein, which is highly 
expressed in brain tissue. Although PICALM is more prominent in microvessels, 
it is also present it neurons, astrocytes and oligodendrocytes (Baig et al., 2010; 
Bushlin et al., 2008; Parikh, Fardo, et al., 2014). PICALM mRNA expression is 
associated with AD risk SNP genotype, rs3851179, when cell type variation is 
included in the analysis. Furthermore, there are multiple splice variants present in 
the brain. Abundance of the splice variants expressed in brain was quantified by 
qPCR. The most abundant splice variant lacks exon 13, followed by exon 18-19, 
exon 2 and exon 2-4.  It is critical to grasp an understanding of these splice 
variants as they will facilitate a better understanding of the molecular 
mechanisms influencing functionality of the protein.  
 
 An allelic expression imbalance (AEI) study was conducted to further 
study the association between rs3851179 and PICALM. Overall, the AD 
associated SNP rs3851179 does not demonstrate a detectable effect on global 
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PICALM AEI. However, a genetic variant, rs588076, subtly modulates a PICALM 
isoform lacking exons 18 and 19. Furthermore, an individual sample shows 
PICALM AEI.  These results collectivity signify the intricacy of PICALM 
expression in the brain and thereby provide insights into current AD-related 
mechanisms studies, which have been largely conflicting and inconclusive. 
 
Discussion and Future Directions 
There are multiple implications of the presented findings. First, total mRNA 
PICALM expression was quantified using qPCR. Association of PICALM 
expression with rs3851179 was only seen when the statistical model was 
corrected with different cell type markers, i.e., neurons, astrocytes and 
microvessels, as covariates. The linear relationship between PICALM and 
different cell type markers is consistent with the immunohistochemical (IHC) 
results, where PICALM was present in microvessels and other cell types. The 
epitope for this particular antibody is the last 18 amino acids in the carboxyl-
terminus of the protein, which is present in all isoforms of PICALM. Although 
several studies have tried to characterize and associate PICALM protein 
expression to AD phenotype in AD brains and AD animal models, only few 
studies have characterized mRNA expression (Allen et al., 2012; Baig et al., 
2010; Karch et al., 2012; Parikh, Fardo, et al., 2014; Thomas et al., 2011). Allen 
et al, Baig et al and Karch et al did not detect an association between PICALM 
and AD, similar to our results. We analyzed the relationship between AD risk 
SNP, rs3851179, and mRNA expression. The rs3851179A allele is associated 
with increased mRNA expression; however, this expression may be modulated 
by the polymorphism in a cell-type specific manner because discerning the 
association between PICALM expression and rs3851179 was contingent upon 
including microvessel mRNA as a covariate within the regression model. 
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PICALM has been shown to be involved in intracellular trafficking, synaptic 
function and clathrin coated vesicle assembly (Harel et al., 2011; Harel, Wu, 
Mattson, Morris, & Yao, 2008). Currently, functional studies primarily focus on 
APP processing and subsequent toxic Aβ production to elucidate the role of 
PICALM expression in AD pathology (Kanatsu et al., 2014; Treusch et al., 2011; 
Xiao et al., 2012). Within the amyloidogenic pathway, APP is endocytosed from 
plasma membrane via CME and cleaved by secretase to produce toxic Aβ 
(Nordstedt, Caporaso, Thyberg, Gandy, & Greengard, 1993). The protective 
allele is associated with increased expression of the gene. Assuming mRNA 
expression is comparable to protein expression, increased expression of 
PICALM has been shown to influence the size and shape of the clathrin coated 
vesicle, as well as reduced function (Meyerholz et al., 2005; Tebar et al., 1999). 
Reduction in endocytosis of APP results in reduced Aβ release (Koo & Squazzo, 
1994). In yeast and in rat neurons, PICALM has been shown to alter Aβ toxicity. 
Increasing PICALM decreased Aβ toxicity in a dose dependent manner (Treusch 
et al., 2011). Two other in vitro studies have shown opposite effect of increased 
PICALM, where increased PICALM expression, increased Aβ release as a result 
of increased APP endocytosis or increased gamma secretase endocytosis 
(Kanatsu et al., 2014; Xiao et al., 2012). However PICALM may not be the only 
culprit, AP180 is a homologue of PICALM and present exclusively in neurons. 
AP180 is also an accessory protein for CME and performs similar function. When 
PICALM and AP180 were decreased by RNAi by Wu et al. only AP180 
knockdown affected Aβ generation (Wu, Matsuoka, Mattson, & Yao, 2009). 
PICALM and AP180 may compensate for one another in neurons or they may be 
dedicated to different processes in neurons (Bushlin et al., 2008; Wu et al., 2009; 
Wu, Mattson, & Yao, 2010). 
  
PICALM is also present in microvessels, microglia and astrocytes (Ando et 
al., 2013; Karch et al., 2012; Parikh, Fardo, et al., 2014). The functional role of 
PICALM in these cell types is not well characterized. Our data show that PICALM 
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is highly expressed in microvessels and correlates positively with endothelial cell 
markers.  This high localized expression suggests that PICALM actions in 
microvessels may be critical to PICALM actions in AD.  One possible functional 
role for PICALM in microvessls Aβ clearance through the blood brain barrier. 
Theoretically, Lipoprotein Receptor-related Protein 1 (LRP1) can bind to Aβ in 
the brain and transport Aβ into the bloodstream by CME and exocytosis (Deane 
et al., 2004; Harasaki, Lubben, Harbour, Taylor, & Robinson, 2005). LRP1 can 
bind to Aβ indirectly thorough APOE (Bu, 2009). In one GWAS, PICALM showed 
significant reduced risk for AD when corrected for APOE4 genotype, suggesting 
a link between APOE and PICALM (Jun et al., 2010; Sweet et al., 2012). 
Increased PICALM expression, may increase CME of APOE-Aβ complex bound 
to LRP1, promoting clearance of Aβ. An association between CSF Aβ42 level 
and PICALM AD risk SNP, further support this hypothesis (Schjeide et al., 2011). 
However, APOE and CSF Aβ42 level did not associate with rs3851179 in 
replication study and further meta-analyzes study (Kauwe et al., 2011; Naj et al., 
2011).   
  
Implications of splice variants on function 
 I have identified over 20 different splice variants for PICALM. The role of 
PICALM protein encoded by these variants has not been thoroughly researched. 
Several isoforms lack key domains and protein binding motifs needed for proper 
function. There are three sites important for AP2 binding. Meyerholz et al. have 
described the importance of these sites and their effect on PICALM function in 
clathrin cage formation and size. The most abundant PICALM isoform lacks exon 
13, which encodes a DPF binding motif that binds to AP2 (Meyerholz et al., 
2005). Similarly, some isoforms lack exons 18-19 which encode a protein domain 
that is important for clathrin binding (Scotland et al., 2012). Lastly, isoforms that 
lack exon 2 have a premature stop codon and encode a truncated PICALM 
fragment (Figure 1.2). There are multiple adaptor and accessory proteins 
involved in CME which may enable PICALM to be still functional in different 
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processes, such as cell proliferation, endosome transport, and vesicle transport 
(Dreyling et al., 1996; Meyerholz et al., 2005; Scotland et al., 2012; Tebar et al., 
1999). Different isoforms could be important for different processes. PICALM 
bound to AP2 has been shown to be involved in degradation of the APP carboxyl-
terminus fragment, isoforms lacking exon 13 and/or 14 could influence this 
process since isoforms lacking these exons would encode a protein with reduced 
AP2 binding capability; whereas isoforms lacking exons 18-19 could reduced 
endocytosis of APP from plasma membrane since isoforms lacking exons 18-19 
would have reduced clathrin binding and subsequently reduced CME (Tian, 
Chang, Fan, Flajolet, & Greengard, 2013; Xiao et al., 2012). Endocytosis studies 
with protein encoded with these PICALM variants isoforms could lead to a better 
understanding of the criticality of these variants. 
 
PICALM isoforms can be cell type specific or the level of expression may 
be cell type specific. Our results show that D13, D18-19, and D2 isoforms 
correlate positively with microvessel mRNA and GFAP, but negatively with SYN; 
whereas the D2-4 isoform correlates positively with neuronal marker SYN (Table 
2.2) This means exons 2-4 could be preferentially spliced by neurons to produce 
D2-4. Although D2-4 is a rare isoform, it produces a truncated protein that would 
be non-functional. When Ando et al. used three different antibodies to stain 
PICALM in human brain tissue, the antibody binding the epitopes encoded within 
exon 10, exon 13, and last 18 amino acids of the carboxyl-terminus had different 
immunoreactivity between the three antibodies (Ando et al., 2013). Our results 
indicate that HPA019053 antibody should label stronger in neurons that the other 
two antibodies. The expression and function of these isoforms in specific cell 
types warrant more investigation. 
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Genetic association with splice variants 
The relationship between the primary AD-associated SNP and the SNPs 
that are associated with PICALM splice variants requires further clarification.  
The primary PICALM AD risk SNP is rs3851179. However two other genetic 
variations have associated with PICALM isoforms. The first of these SNPs is 
rs592297, which associated with D2-4 PICALM isoform in our linear regression 
analysis. Rs592297 is a synonymous SNP located within exon 5 and has been 
predicted to be an exon splicing enhancer (Harold et al., 2009; Schnetz-Boutaud 
et al., 2012). Further experimentation is needed to elucidate if rs592297 is a 
functional SNP influencing exon2-4 splicing. If rs592297 is a functional SNP, the 
protein encoded by D2-4 PICALM is incomplete and most likely non-functional. 
This is a rare isoform and the SNP was not robustly associated with AD in GWAS 
(Harold et al., 2009). The impact of this SNP may be low but it could contribute to 
AD risk is a cumulative fashion with rs3851179.  
 
The second SNP that was associated with a PICALM isoform was 
rs588076, which was associated with the D18-19 PICALM isoform. Rs588076 is 
an intronic SNP located within intron 17. Rs588076 may be the functional SNP or 
may be in high LD with the functional SNP to influence splicing of D18-19 
isoform. Eight out of fourteen individuals, heterozygous for rs588076, showed 
significant AEI for D18-19 PICALM. A replicate study with more individuals would 
be beneficial. The SNP itself may not be the functional SNP, rather it may work 
synergistically with another SNP to influence splicing of exons 18 and 19 or it 
may be in high LD with the functional SNP. There were other SNPs within the 
latter part of the gene that were heterozygous in individuals showing high AEI. 
Most of the SNPs were in high LD with each other, thus multiple SNPs could be 
influencing the splicing of exons 18-19 synergistically. Overall, the effect of 
rs588076 on D18-19 PICALM should be further studied to elucidate if rs588076 
is the functional SNP, or another SNP in high LD with rs588076 is the culprit, as 
it may have functional implications beyond AD. 
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Isoforms lacking exons 18-19 encode PICALM that lacks a part of the 
clathrin binding domain of PICALM. How the loss of exons 18-19 translates to 
PICALM function should be further examined. Interestingly, rs588076C allele has 
been associated with systolic blood pressure response to calcium channel 
blocking drug in hypertensive patients (Kamide et al., 2013).  There is 
ambiguouity about how PICALM SNP can be involved in pressure response, 
calcium channel regulation or calcium uptake. To gain greater insight, mRNA 
expression of total PICALM and D18-19 PICALM should be quantified in vascular 
and heart tissue. When we quantified the isoform in brain tissue it was 1-2% of 
total PICALM expression.  However this isoform may be expressed more in other 
tissues. Furthermore, function of the encoded D18-19 PICALM protein should be 
studied relative to vascular smooth muscle cells and factors that influence 
vasodilation of arteries.  
 
Analysis of SNP effect 
 Two primary methods were used to analyze the genetic effect of the AD 
risk SNP rs3851179 on gene expression. First, real time quantitative PCR 
(qPCR) was used to quantify mRNA expression of total PICALM and several 
splice variants, and then statistically analyzed for an association with AD, 
rs3851179, and brain specific cell types.  Second, next generation sequencing 
was used to measure the incidence of SNP alleles to see if alleles are unequally 
represented, i.e., whether one allele is associated with higher expression of the 
gene. Both methods have their strengths and weaknesses. Selected aspects will 
be discussed more thoroughly below.  In brief, the strengths of the qPCR assay 
include: the ability to analyze SNPs in intronic and non-coding region, quantifying 
the gene expression with respect to control genes and standard curve, and 
sensitive analysis of low expression genes. Conversely, the weaknesses of 
qPCR include: inter-individual variability can confound analysis and the ability to 
quantify only one isoform in an assay. Whereas, the AEI study assay can detect 
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multiple isoforms and avoids inter-individual variability by comparing with a 
person. However, the weaknesses of AEI studies includes that the assay 
requires that the genes have a higher expression, a common SNP in the coding 
region of the gene that is detectable with an amplicon of the appropriate size for 
sequencing. 
 
 Intronic or noncoding SNPs can be indirectly studied using the AEI  
method by using marker SNPs within the gene that are in high LD with the SNP 
of interest. Whereas in the qPCR method, any SNP, coding and noncoding, can 
be genotyped and can be analyzed for an association directly. We genotyped 
rs3851179 in our sample set, and quantified PICALM using qPCR for the 
association. Whereas, for the AEI study we used two exonic SNP rs76719109 
and rs592297 as marker SNPs and then further analyzed the data for the AD 
associated SNP. To analyze SNP effect on gene expression, AEI assays require 
exonic SNPs that are sufficiently abundant to ensure numbers of samples that 
are well powered for analysis. 
 
 Another advantage of qPCR is the sensitive quantification of copy 
numbers, whereas in AEI the gene expression is not quantified, rather it is the 
relative comparison of transcript or allele present within the sample. With qPCR, 
expression of PICALM can be compared among isoforms of PICALM as well as 
other genes in the brain; which was especially beneficial to us since our results 
showed a cell type effect. We could only compare PICALM expression to SYN, 
GFAP and microvessel mRNA using the qPCR method. A common concern with 
PCR-based assays is PCR bias.  However in both our qPCR and AEI studies, we 
included standard curves which were linear and hence PCR bias does appear to 
be an issue in our studies. In particular however, we note that we did not 
compare the relative abundance of one transcript to another transcript in the AEI 
studies because of concerns regarding PCR bias between isoforms in this assay. 
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AEI is useful for initial assessment of allele expression, however for more 
multidimensional assessment, qPCR analysis is necessary.  
Another consideration is amplicon size limitations which are present in 
both methods. Although next generation sequencing methods have advanced in 
amplicon length reads, at the time our study the average length read was around 
150-200 bp by Ion Torrent. In qPCR, the amplicons must be less than 200 bp to 
ensure high efficiency amplification. Using qPCR, only one isoform can be 
analyzed at a time. Whereas, with the AEI approach, we were able to analyzed 
three different isoforms in one study. Overall, experimental design was a 
challenge for qPCR and AEI, as there were multiple exons that were alternatively 
spliced. 
 
In our results, we see an association of rs3851179 on total PICALM 
expression using qPCR, however we do not see equal allelic representation in 
the AEI study.  These results have two interpretations.  First, the qPCR assay 
relies upon normalizing the mRNA copy numbers for housekeeping genes, and 
cell type specific markers. For ubiquitously expressed genes, this normalization 
can be beneficial in discriminating cell specific effects. qPCR analyses are 
advantageous in discerning gene effect on expression of a gene present in 
multiple cells. PICALM is expressed in endothelial cells, microglia, astrocytes and 
neurons. The effect of the SNP on gene expression could be more in one type 
than other due to differences in transcription or splicing factors. Normalizing to 
these cell types could help discover an association. In AEI study, samples are 
normalized to the genomic allelic ratio and there is no cell type or housekeeping 
gene normalization. As an example, consider the possibility that PICALM is 
highly expressed in microvessels where there is no SNP effect, compared to 
expression in neurons where there is a SNP effect but there is low copy number 
of the gene. The SNP effect will be masked by the allelic representation of 
microvessel cells mRNA content, because all cells are homogenized in the 
sample. The second of the different results obtained with the qPCR and AEI 
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studies was that the association of PICALM expression with rs3851179 by qPCR 
relies upon statistical association. The statistical association could be due to an 
unknown confounding factor such that the linear regression analysis of qPCR 
results is a statistical artifact.  
 
PICALM in human disease  
 PICALM has been implicated in two human diseases, acute leukemia and 
AD. PICALM was first isolated from the U937 cell line used to study acute 
leukemia. Chromosomal translocation of t(10;11)(p13;q14) results in AF10/CALM 
or CALM/AF10 fusion gene and is associated with poor prognosis (Ben Abdelali 
et al., 2013; Dreyling et al., 1996). The role of the fusion protein in leukemia is 
still being elucidated. There are multiple splice variants present for both genes. In 
the PICALM/AF10 chromosomal translocation, the chromosome breakpoint 
occurs in the latter part of PICALM, usually around intron 17-19 with the resulting 
mRNA encoding in frame and out of frame transcripts (Silliman et al., 1998). 
(Caudell & Aplan, 2008). Although the fusion transcript is rare, the effect of 
rs588076 on exon 18-19 splicing may be critical for the translated leukemogenic 
protein.  
 
PICALM is one of the few genes associated with AD through GWAS. AD 
is a complex disease with complex genetic penetrance. PICALM locus has been 
consistently associated with AD, however, there has been debate if PICALM 
SNPs are protective in all populations and/or if rs3851179 is the primary AD 
associated SNP for the gene (Harold et al., 2009; Naj et al., 2011; W. Xu, Tan, & 
Yu, 2014). It is unclear how the SNP maybe be contributing to the GWAS 
outcome. A number of studies have expounded the role of the PICALM protein in 
AD pathological pathway. However, few studies have tried to elucidate the 
function of the AD SNP genotype in regulating expression and splicing of 
PICALM. The SNP itself is ~80,000 bp from the coding region of the gene, 
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suggesting that this SNP may be in LD with the functional SNP within the gene, 
in the PICALM promoter region, and/or located on a distant-acting transcriptional 
regulatory element. 
 
To understand the effect of the SNP on AD, the effects of the AD 
associated SNP on PICALM mRNA must be elucidated. The rs3851179A minor 
allele is protective for AD risk. Our qPCR results show that presence of A allele is 
associated with increased total PICALM and D13-PICALM expression. I interpret 
these results as having two possible meanings.  The first interpretation focuses 
on total PICALM.  An increase in total PICALM expression results in increased 
PICALM expression, which disrupts CME by altering clathrin coated vesicle size 
and shape.  This, in turn, reduces endocytosis of proteins like transferrin.  In 
contrast, increased PICALM has ben shown to increase encocytosis of proteins 
like APP, leading to increased Aβ production (Tebar et al., 1999; Xiao et al., 
2012). Thus, increased PICALM could result in a loss of function, as shown by 
Tebar et al., because disruption of CME reduces transferrin endocytosis.  
However, increased PICALM could be a gain of function resulting in increased 
Aβ. The effect of PICALM may be in modulating in a ligand specific manner. The 
second interpretation of the SNP association focuses upon increased D13-
PICALM expression.  This would result in increased PICALM protein that has 
reduced functional capability and thus decreased CME. Hence, the protein 
encoded by isoforms lacking exon 13 needs to further studied within the AD 
pathway. Overall, there is still debate whether overexpression of PICALM 
exacerbates or rescues AD phenotypes or pathology.  Further studies with 
different protein isoforms could elucidate PICALM function in AD.   
 
One would hope that understanding how rs3851179 modulates PICALM 
expression and splicing to influence AD risk may allow us to develop novel 
therapeutics that mimic the protective effects of this SNP, and thereby reduce AD 
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risk. However this will be challenging because PICALM is ubiquitously expressed 
and endocytosis is a critical process for many physiological processes. 
Furthermore, alterations in PICALM expression have varied results on clathrin 
coated vesicle size and shape and CME (Meyerholz et al., 2005; Tebar et al., 
1999). Up regulating or down regulating PICALM might require a fine balance 
rather than sheer expression changeability. Evaluating actions of AD associated 
SNP on PICALM expression and subsequent protein expression will determine 
the effects of encoded isoforms on CME and thereby provide insights into AD-
related mechanisms.  
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